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List of Figures
Figure 1.1 Perfluorocarbon nanoparticle (~250 nm diameter) theranostic contrast agent can be
functionalized by inserting various targeting ligands and drug payloads into the
lipid monolayer. [Graphics courtesy of Kereos, Inc.]
Figure 1.2 Gd-bearing nanoparticles targeted to angiogenesis provide T1-weighted signal to
create 3D maps of neovasculature. 3D Neovasculature maps indicating “angiogenic
switch” in VX2 tumor. Bars indicate percent of tumor volume enhancing. [Figure
reprinted with permission from Schmieder et al.]
Figure 1.3 (Top) Black blood image of the thoracic aorta (arrow) and segmentation of the
vessel wall (outlined in yellow) is shown for the week 0 image. The color-coded
overlay of signal enhancement (%) shows patchy areas of high angiogenesis. On the
week 1 image, the signal enhancement has clearly decreased due to the
antiangiogenic effect of targeted fumagillin treatment. (Bottom) The level of signal
enhancement gradually increases at weeks 2 and 3 after fumagillin treatment, until
week 4, when the level of enhancement is practically identical to the week 0 image.
[Figure reprinted with permission from Caruthers et al.]
Figure 1.4 Cardiac magnetic resonance signal enhancement up to 8 weeks after treatment with
targeted fumagillin nanoparticles with and without oral atorvastatin. (Top) Cardiac
magnetic resonance enhancement in untreated (triangles), atorvastatin-treated
(circles) and fumagillin-treated animals (squares) during 8 weeks of follow-up
imaging. Untreated and statin-treated animals showed a constant level of
angiogenesis in the aortic wall. Animals treated with targeted fumagillin
nanoparticles at 0 and 4 weeks showed decreased angiogenesis (*p < 0.05) after
each dose, which returned to baseline levels within 4 weeks. (Bottom)
Enhancement in rabbits receiving atorvastatin alone (triangles) or in conjunction
with 1 (squares) or 2 (circles) doses of targeted fumagillin nanoparticles. The
combination of 2 fumagillin doses and statin produced a sustained decrease in
angiogenesis (*p < 0.05). [Figure reprinted with permission from Winter et al.]
Figure 1.5

19

F imaging and spectroscopy of crown ether nanoparticles bound to fibrin in
ruptured plaque of human carotid artery specimen. The separate 1H and 19F images
(top, left) can be combined with 19F overlaid on 1H anatomy (magnified, right).
[Figure reprinted with permission from Caruthers et al.]

Figure 1.6 Left: T1-Weighted Imaging of Fibrin Clots. (A) Paramagnetic CE nanoparticles,
bound to the clots in cross section, appear as a bright line of signal enhancement
with intensity decreasing linearly as the concentration of paramagnetic CE
nanoparticle decreases (left to right). Maximum intensity projection through the 3D
data depicts the clots en face (B). Mid Left: Volume selective 19F spectra from clots
show the concentration of crown ether (CE) decreases inversely with perfluorooctyl
bromide (PFOB). Mid Right: 19F MR Imaging of PFC NP Bound to Fibrin Clots.
These three fluorine images, which have no proton “background,” are oriented
vii

perpendicular to the clots as in A. They illustrate the fibrin-bound PFC
nanoparticles of various mixtures applied to the clots. In a broad bandwidth
excitation (top), all fibrin clots enhance brightly. Narrow bandwidth excitation
allows independent visualization of the CE or PFOB nanoparticles. Right: 19F
Image-based quantification allows relative quantification of NP concentration on
clots. [Figure reprinted with permission from Caruthers et al.]
Figure 1.7

19

F MRI (ex vivo) of disrupted human carotid artery endarterectomy specimen with
atherosclerotic plaque and overlying thrombus using fibrin-targeted PFC NP. Left:
an optical image of a human carotid endarterectomy sample shows moderate
luminal narrowing and several atherosclerotic lesions. Middle: A 19F projection
image acquired through the entire thickness of carotid artery sample shows high 19F
signal along the lumen because of the binding of nanoparticles to fibrin. Right: The
calculated concentration map of bound nanoparticles (nM) in the carotid sample
based on 19F signal intensity in each voxel. [Figure reprinted with permission from
Morawski et al.]

Figure 1.8 Localization of PFC NPs labeled cells in mice using 19F MRI. (a) 19F MRI
trafficking of stem/progenitor cells labeled with either perfluorooctyl bromide
(PFOB) (green) or perfluoropolyether (PFPE) (red) nanoparticles. Labeled cells
were locally injected into the skeletal muscle of mouse thigh before MRI. (b)–(d)
At 11.7-T field strength, 19F spectral discrimination permits respective imaging of
∼ 1×106 PFOB-loaded cells (b) and PFPE-loaded cells (c). The composite 19F
(displayed in color) and 1H (displayed in grayscale) images (d) reveal the location
of PFOB labeled cells in the left leg and PFPE labeled cells in the right leg (dashed
line indicates 3 × 3 cm2 field of view for 19F images). [Figure reprinted with
permission from Partlow et al.]
Figure 1.9 The imaging chain of a commercial MR scanner includes many steps in which
measurements and adjustments are made, from determining the power settings for
accurate flip angles, to B0 shimming, to inhomogeneities in B1 for RF transmit and
receive; even during the scan eddy currents, B0 variations, J-coupling, etc. can
affect quantification outcomes.
Figure 2.1 Left: Longitudinal (spin-lattice) relaxation, described by T1 relaxation time. Right:
Transverse (spin-spin) relaxation, described by T2 relaxation time.
Figure 2.2 Timing diagram for a 90° RF pulse (top) followed by a free induction decay (FID)
signal (bottom) of net magnetization in the transverse plane, detectable by a RF
receiver coil.
Figure 2.3 Left: Chemical structure of perfluoro-15-crown-5-ether (PFCE). 19F NMR spectrum
of PFCE, resulting in a single resonance peak since all 19F nuclei experience the
same local magnetic field.

viii

Figure 2.4 (a) Chemical structure of perfluorooctyl bromide (PFOB; CF3-(CF2)6-CF2Br). (b)
Representative MR spectrum of PFOB. The J-coupling constant between CF3 and
the adjacent CF2 group is 12.3 Hz.
Figure 2.5 Schematic diagram of a coupled resonator circuit. (a) the resonator formed by
capacitor Ct2 and probe (with inductance L) is capacitively coupled, by capacitor Cc,
to the secondary resonator formed by capacitor Ct1 and inductor L. (b & c) the
equivalent circuit of in-phase and anti-phase mode. (d) coupled resonator is
capacitively matched to 50 Ohm with Cm. [Figure reprinted with permission from
Hu et al. (29)]
Figure 2.6

19

F/1H dual-tuned RF coil circuit. (a) Equivalent circuit diagram of two separate
LCR resonators (L1, C1, R1) and (L2, C2, R2) electrically coupled via capacitor C3.
(b) Image of second resonator circuit with coupling capacitors (C3A and C3B) and
matching capacitors (C4A and C4B) labeled. (c) Theoretical impedance magnitude
output of a SPICE simulation of two capacitively coupled resonators. [Figure
reprinted with permission from Hockett et al. (28)]

Figure 2.7 Photographs of single-turn solenoid RF coils. (a) Smaller coil (8 cm diameter). (b)
Larger coil (11.5 cm diameter). (c) T/R box that interfaces with clinical scanner.
Figure 2.8 Simultaneous dual-frequency return loss (S11) of single-turn solenoid coil
measured using network analyzer. Return loss, better than -30 dB, is observed at
both the 1H (127.8 MHz) and 19F (120.2 MHz) resonance frequencies.
Figure 2.9 Arrangement of capacitors used to spread out the current in the 8 cm diameter
19 1
F/ H dual-tuned single-turn solenoid coil.
Figure 2.10 (a) T1-weighted 1H FFE image of saline phantom using 8 cm diameter 19F/1H dualtuned solenoid coil. (b) Signal intensity profile over the distance of the phantom, as
indicated.
Figure 2.11 (a) AFI B1 map of saline phantom using 8 cm diameter 19F/1H dual-tuned solenoid
coil (119.76% ± 0.03% actual/requested flip angle). (b) AFI intensity profile over
the distance of the phantom, as indicated.
Figure 2.12 1H (a) and 19F (b) images of a rat lung model of asthma using simultaneous 19F/1H
imaging of ανβ3-integrin targeted PFC NP.
Figure 3.1 a: Perfluorooctyl bromide (PFOB: CF3-(CF2)6-CF2Br) 19F spectrum. b: All
chemical shift components of PFOB CF2 line group (β, γ, δ, ε, ζ, ρ) remain within a
phase range of ± 90° for 0.5 ms. c: 19F signal evolution of the (CF2)6 line group with
and without apparent T2 relaxation. During a fast FID readout as in the balanced
UTE-SSFP technique, the relative signal remains above 60%, which cannot be
recovered for later echo times. [Figure reprinted from Goette, et al. In press]
ix

Figure 3.2 A simultaneous 3D 19F/1H balanced UTE-SSFP pulse sequence, consisting of
simultaneous 19F/1H RF excitation and subsequent FID acquisition at an ultra-short
echo time, using balanced gradients (m, mr) with a Wong-type (39) radial readout
trajectory. [Figure reprinted from Goette, et al. In press]
Figure 3.3 Magnitude 19F image of sensitivity imaging phantom, showing PFOB signal
acquired with balanced UTE-SSFP sequence. ROI show locations of 19F signal (I0)
[middle], and noise [right] used for SNR calculations. [Figure reprinted from
Goette, et al. In press]
Figure 3.4 Molecular imaging of ανβ3-integrin targeted NP on VX2 tumors (arrows) in rabbits
by 19F MRI. Gd-free (a,b,c) or Gd-containing (d,e,f) NP with a perfluorooctyl
bromide (PFOB) core were used and imaged with a novel balanced UTE-SSFP
based 3D radial sequence. 1H images show T1-based enhancement only with Gd NP
(d), while the 19F signal is clearly detected in both cases (b&e). Image overlays
(c&f) demonstrate the anatomical co-localization. [Figure reprinted from Goette, et
al. In press]
Figure 3.5 Simultaneous 19F/1H molecular imaging of angiogenesis targeted perfluorooctyl
bromide nanoparticles in a rabbit model of atherosclerosis using 3D radial balanced
UTE-SSFP. Proton image (a) with 1.25 mm isotropic voxels show anatomy, upon
which 19F image can be overlaid (b). The ROI in (b) is surrounding the aorta, which
has a diameter of about 5 mm. The 19F overlay within the aortic region is in green,
and extra-aortic 19F signal is blue.
Figure 3.6 Modeled steady-state gradient echo signal as a function of flip angle (α) for
balanced SSFP (“R-FFE”, red line), GRE (“N-FFE”, blue line), and RF-spoiled
GRE (“T1-FFE”, green line) using an estimated actual T2 of 110 ms.
Figure 4.1
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F/1H dual-tuned RF coils. (a) Single loop rectangular surface coil (7×12 cm,
Philips Healthcare, Best, The Netherlands). (b) Custom-built 6-element semicylindrical coil (15 cm diameter), and (c) single-turn solenoid coil (11.5 cm
diameter, 14 cm length). [Figure reprinted from Goette, et al. In review]

Figure 4.2 Representative flip angle sweep (10°-210°) on 19F nucleus (top) and 1H nucleus
(bottom) using the same power setting (peak power = 122.9 W) with a 19F/1H dualtuned surface coil indicating correct power settings for 19F, but too high for 1H.
[Figure reprinted from Goette, et al. In review]
Figure 4.3 3D Ball plot representation of optimized RF power settings (peak power, W) for 19F
(a) and 1H (b) nuclei using a 19F/1H dual-tuned surface coil and a point source
phantom of PFCE NP emulsion. (c) Ratio of optimum 19F/1H power setting yields a
spatially independent calibration value (1.48 ± 0.06 for surface coil). [Figure
reprinted from Goette, et al. In review]
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Figure 4.4 Power settings (peak power, W) needed to optimize 90° flip angle for 19F and 1H
signals from point source phantom at 9 mm, 15 mm, and 27 mm above 19F/1H dualtuned surface coil (a), semi-cylindrical coil (b), and within single-turn solenoid coil
(c). [Figure reprinted from Goette, et al. In review]
Figure 4.5

19

F MRI of phantom with two vials of 1.0 M NaF in agar using a simultaneous
F/1H bFFE sequence and a 19F/1H dual-tuned surface coil. Before correction, 19F
image (a) and 19F/1H overlay image (b) illustrate the inhomogeneous RF field
produced by the surface coil, resulting in a mean signal intensity of 2537 ± 31 a.u.
and 863 ± 7 a.u. in each vial. 1H B1-field was mapped with actual flip angle imaging
(% actual/requested FA) (c), and input into bFFE signal model to create a correction
factor (d), which was used to compensate 19F and 1H signal intensities. The
corrected 19F image (e) and 19F/1H overlay image (f) demonstrate the image-based
compensation technique, resulting in a mean signal intensity of 2621 ± 27 a.u. and
2681 ± 23 a.u. in each vial. [Figure reprinted from Goette, et al. In review]
19

Figure 4.6 One-way ANOVA analysis of the 19F signal intensity from phantom of two PFC NP
vials (1: closer to coil; 2: farther away) before (left) and after (right) B1-mapping
compensation.
Figure 4.7

19

F MRI of homogeneous phantom (1.0 M NaF in 2% agar) using a simultaneous
F/1H bFFE sequence and a 19F/1H dual-tuned surface coil. Before correction, 19F
image (a) and 19F/1H overlay image (b) show result of inhomogeneous RF field
produced by surface coil. 1H B1-field was mapped with actual flip angle imaging (%
actual/requested FA) (c), and input into bFFE signal model to create correction ratio
(d), which was used to correct 19F and 1H signal intensities. Corrected 19F image (e)
and 19F/1H overlay image (f) demonstrate image-based correction technique.
[Figure reprinted from Goette, et al. In review]
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Figure 4.8 B1-mapping compensation of in vivo cancer model in rabbit with the use of ανβ3integrin-targeted PFC NP nanoparticles captured by 19F MRI with a 19F/1H dualtuned surface coil (located at image right). In the uncorrected 19F image overlaid on
the high-resolution 1H image (a), PFC NP concentration was quantified as 20.0 ±
0.12 mM19F, compared to an external standard of known concentration (150
mM19F). Illustrated are: B1-field mapping with AFI (% actual/requested FA) (b) and
calibration mask calculated from a balanced UTE-SSFP signal model (c). In the
corrected 19F image overlaid on the high-resolution 1H image, PFC NP
concentration was quantified as 25.5 ± 0.10 mM19F. [Figure reprinted from Goette,
et al. In review]
Figure 5.1 (a) 1H TSE image of unilateral permanent occlusion of renal artery in rat left
kidney. (b) 19F bFFE image of PFCE NP emulsion injected i.v. (3 ml/kg). Location
of kidneys outlined in red (arrow: injured left kidney). (c) 19F image false-colored in
green overlaid on 1H image.
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Figure 5.2 (a) 1H TSE image of ex vivo rat kidney cross-section showing cortex [C] and
medulla [M]. In vivo rat kidney cross sections showing renal perfusion via 19F
imaging of PFCE NP emulsion (3 ml/kg) in the following: (b, c) normal controls-L,
R; (d, e) permanently occluded-L, contralateral control-R; (f, g)
ischemia/reperfusion-L, contralateral control-R. (h, i) Ex vivo 19F imaging of
ischemia/reperfusion-L, contralateral control-R.
Figure 5.3 (a) Cross-sectional 1H image of rat anatomy, showing left injured kidney in an
ischemia/reperfusion model of AKI and external 19F standard outlined in red. (b)
19
F MR image using simultaneous 19F/1H bFFE sequence of PFCE NP emulsion (3
ml/kg) circulating for 5 min. Compared to external PFCE standard (150 mM19F), 19F
signal was quantified in the kidney, which showed lower renal perfusion in the
medulla (63.8 ± 10.9 mM19F) than in the cortex (82.8 ± 6.9 mM19F). (c) 19F image
overlaid in green on 1H image showing colocalization of standard and renal 19F
signal. (d) B1 map using AFI (% actual/requested flip angle) demonstrating that
nearly the same flip angle was achieved in the 19F standard (95.2 ± 6.0 %) as in the
kidney (95.9 ± 3.4 %) with the 19F/1H dual-tuned solenoid coil.
Figure 5.4 (a) Long-axis 1H image of rat anatomy, showing left injured kidney in an
ischemia/reperfusion model of AKI outlined in red. (b) B1 map using AFI (%
actual/requested flip angle) showing homogeneous RF field within field-of-view
(FOV) (~ 5 cm long) of 19F/1H dual-tuned solenoid coil (c), which falls off outside
coil FOV.
Figure 5.5
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F MRI of 1 ml/kg PFC NP emulsion injected into normal chow rabbit 3 min prior
to imaging. (a) 19F bFFE image without REST slab shows long-axis view of the
rabbit, with 19F signal detectable in aorta, liver, and kidney, confirmed with
colocalization in 19F/1H overlay image (c). A REST slab perpendicular to the
imaging slice eliminates 19F signal from image (b & d). REST slab and imaging
slice location (e).

Figure 5.6 Cross-sectional 19F MR images without (a) and with (b) one parallel REST slab
proximal to the imaging slice, which eliminates only aortic 19F signal from
circulating PFC NPs, confirmed with 19F overlays (green) on 1H images (c & d).
Figure 5.7 Locations of saturation bands used to eliminate 19F signal from flowing blood
proximal and distal to imaging slice (which continued beyond the image FOV).
Aorta, shown in red, was imaged with a time-of-flight angiogram. [Figure reprinted
from Palekar, Goette, et al. In preparation]
Figure 5.8 Cross-sectional 1H images of (a) normal chow rabbit and (d) cholesterol fed rabbit
showing location of abdominal aorta (red box). 19F bFFE images of PFCE
nanoparticle 19F signal in the region of interest for (b) normal chow rabbit and (e)
cholesterol fed rabbit. Saturation bands proximal and distal to imaging slice
eliminate 19F signal from blood. 19F signal (green) overlaid on 1H image showing
19
F signal colocalization for the region of interest in a (c) normal chow rabbit and
xii

(f) cholesterol fed rabbit, demonstrating deposition of PFC-NP only in inflamed
abdominal aorta (AA) and vena cava (VC). Representative oil red O stains of the
imaged area showing plaque elements in (g) normal chow rabbit and (h) cholesterol
fed rabbit. Scale bars denote 500 µm. [Figure reprinted from Palekar, Goette, et al.
In preparation]
Figure 6.1 (a) T1-weighted 1H FFE coronal image of leg phantom. Setup of MR angiography
of phantom with flowing (~ 8 cm/s) saline doped 5000:1 with Gd3+ using M2D TOF
(multiple 2D, time-of-flight) 1H imaging with REST slab position (b). MRA
maximum intensity projection (MIP) and MIP overlay on 1H image without (c&d)
and with a REST slab (e&f) saturating the spins in the return flow.
Figure 6.2 (a) Semi-cylindrical 19F/1H dual-tuned coil. (b) Leg phantom, consisting of tubing
encased within 2% agar in 2L bottle. Actual Flip Angle Imaging (%
Actual/Requested Flip Angle) maps in the transverse (c) and sagittal (e) views with
corresponding profile plots (d & f) increasing in distance away from the coil
(location illustrated in red).
Figure 6.3 T1-weighted 1H FFE transverse (a) and coronal (b) images of leg phantom.
Simultaneous 19F/1H imaging of PFCE NP emulsion in leg phantom tubing (static)
using bFFE sequence in transverse (c) and coronal (d) planes. Note: banding
artifacts from coil are present in coronal slice. 19F image using balanced UTE-SSFP
sequence in transverse plane (e), with coronal MIP (f).
Figure 6.4 MR angiography of leg with flowing (600 ml/hr) saline using M2D TOF (multiple
2D, time-of-flight) 1H imaging. Maximum intensity projections (MIP) in coronal
(a), sagittal (b), and transverse (c) planes. MRA setup and slice orientation (d).
Figure 6.5 (a) High-resolution T1-weighted 1H FFE transverse image of leg anatomy (arrow:
cannulated artery). (b) 19F imaging of PFCE NP emulsion (~ 2 ml/kg) in artery
using balanced UTE-SSFP sequence in transverse plane. Other 19F signal from PFC
NP emulsion that pooled outside the specimen due to leaking from an absence of a
return circuit.
Figure 7.1 Unique 19F/1H dual-tuned coil design (left) and circuit diagram (right) with active
switching, allowing for transmission using an outer coil element and reception
using an inner coil element.
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Medical imaging is undergoing a transition from an art that is used to make static images
of human physiology into a scientific tool that employs advanced techniques to measure
clinically relevant data. Recently, the role of magnetic resonance imaging in cardiovascular and
oncological research has grown, largely due to the implementation of new quantitative
techniques in the clinic. Magnetic resonance imaging (MRI) and spectroscopy (MRS) are
particularly rich in their capability to quantify both physiology and disease via biomarker
detection. While this is true for many applications of MRI in cardiovascular and oncological
research, 19F MR molecular imaging is particularly useful when coupled to the use of emerging
site-targeted molecular imaging agents for diagnosis and therapy, such as αvβ3 integrin-targeted
perfluorocarbon (PFC) nanoparticle (NP) emulsions. Unfortunately, the radiological world is
realizing that although image quality may be consistently high, the absolute quantitative values
being calculated vary widely across time, techniques, laboratories, and imaging platforms.
xviii

The overall objective of this work is to advance the state of the art for 19F MR molecular
imaging of perfluorocarbon nanoparticle emulsion contrast agents. To reach this objective, three
specific aims have been identified: (1) to create new tools and techniques for 19F MR molecular
imaging of PFC nanoparticles, (2) to develop translatable procedures for absolute quantification
of 19F nuclei with MR molecular imaging, and (3) to evaluate the potential for clinical translation
with ex vivo and in vivo preclinical experiments. Robust, standardized techniques are developed
in this work to improve the accuracy of in vivo quantitative 19F MR molecular imaging, validate
system performance, calibrate measurements to ensure repeatability of these quantitative metrics,
and evaluate the potential for clinical translation. As these quantitative metrics become routine in
medical imaging procedures, these standardized calibrations and techniques are expected to be
critical for accurate interpretation of underlying pathophysiology. This will also impact the
development of new therapies and diagnostic techniques/agents by reducing the variability of
image-based measurements, thereby increasing the impact of the studies and reducing the overall
time and cost to translate new technologies into the clinic.
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Chapter 1. Introduction

1.1 Quantitative Magnetic Resonance Molecular and Functional Imaging
Medical imaging is undergoing a transition from an art that is used to make static images
of human physiology into a scientific tool that employs advanced techniques to measure
clinically relevant data. This is particularly true for magnetic resonance imaging (MRI), which
has been widely adopted as a powerful diagnostic imaging modality with superior soft tissue
contrast and an excellent human safety profile, due to a lack of ionizing radiation (1). MRI is
increasingly being used to generate quantitative metrics of human physiological function, as seen
in the clinic with measurements of myocardial function and viability (2), apparent diffusion
coefficient in acute stroke (3), blood flow velocity through a stenotic vessel (4), and first-pass
contrast agent kinetics (5), among many others. Alongside the implementation of new imaging
procedures is the development of new contrast agents, which include targeted imaging agents
and detectable therapeutics. The potential of these “theranostic” agents to offer personalized
diagnosis, precise therapy delivery, and unparalleled post-therapy response arises from their
quantitative nature (6).
Molecular imaging offers extraordinary potential for studying cell biology, detecting
disease biomarkers, and monitoring targeted drug delivery using noninvasive techniques (7-11).
Its hallmark is the ability to visualize and characterize the presence of specific cellular indicators
of biological processes using a variety of targeting ligands, such as fibrin (12), ανβ3 integrin (13),
epidermal growth factor receptor (EGFR) (14), and vascular cell adhesion molecule 1 (VCAM1) (15). Perhaps more profoundly and clinically useful is the potential for quantification, not only
of biomarkers, but also of targeted drug delivery and therapy response (16-18). While relative
1

values derived from images are helpful, absolute and accurate measures are required for preclinical and clinical studies, as well as ultimate clinical therapy utility. Accurate and stable
quantification is especially vital where time-varying biomarker information is required, such as
in pharmacodynamic studies.
Functional imaging presents an opportunity to observe and quantify pathophysiological
changes to tissue or organ functionality in response to disease or external stimulus. Recent
developments in MRI techniques and contrast agents afford numerous opportunities for direct
and noninvasive readouts of essential functional indexes such as diffusion (19), perfusion (5), pH
(20), and blood oxygenation (21). Since molecular and functional imaging offer different but
complementary insights into the same pathophysiological processes, there is a growing interest
in devising reliable platforms that permit accurate and repeatable quantitative molecular and
functional readouts of the underlying biological mechanism of disease states in a more
comprehensive manner (22,23).
While molecular and functional imaging are generally robust due to the combination of
various imaging modalities, magnetic resonance imaging alone is a rich molecular and functional
imaging modality because of the inherent ability to image various contrasting tissue
characteristics, and the ability to take spectroscopic and parametric measurements. Most current
MR techniques are qualitative (i.e., relative), often requiring pre- and post-agent imaging with
subsequent image registration and comparison. Current “absolute” methods are still, in reality,
relative measures in that they vary temporally and spatially within an imaging system (e.g., due
to hardware sensitivity, tuning, scaling, etc.) and across imaging systems (e.g., due to differences
in hardware, techniques, etc.).
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As these new quantitative imaging techniques undergo clinical evaluation, their precision,
accuracy, and repeatability must be fine-tuned and standardized before they can be fully
integrated into the clinical setting. Robust methods of quantitative imaging will also be essential
in the pre-clinical development of novel contrast agents, therapeutics, and diagnostic protocols.
Just as imaging techniques with known endogenous and exogenous contrast mechanisms require
thorough testing, the eventual translation of these new agents into the clinic will require robust,
precise, and repeatable quantitative imaging protocols.

1.1.1 Proton MR Molecular and Functional Imaging
Magnetic resonance molecular and functional imaging is generally divided into two
options based on the imaging nucleus of choice: proton and non-proton. Non-proton MRI is
employed to directly visualize clinically relevant exogenous contrast agents or molecules that
contain nuclei other than hydrogen exhibiting net nuclear spin in external magnetic fields. Proton
imaging utilizes intrinsic or agent-induced local relaxation modulation of hydrogen (1H) nuclei,
which contain a single proton and no accompanying neutron. In proton imaging, detected 1H
spins are correlated with the expression of biochemical markers or the quantitative value of
specific functional indexes. 1H MR molecular and functional imaging offers a wide variety of
contrast mechanisms that can be utilized by modifying the contrast agent, pulse sequence, and
imaging protocol. Contrast can be generated either by manipulating endogenous tissue relaxation
properties, or by detecting the effects of exogenous contrast agents.
Several relevant endogenous contrast-based functional imaging approaches are in or
entering clinical use. Among them, diffusion tensor MRI (DTI) correlates water diffusion in soft
tissue with a magnetic resonance readout and delineates tissue microstructures resulting from
3

restricted boundaries for water diffusion (19). Arterial spin labeling (ASL) utilizes a special
pulse sequence and applies RF power to magnetically label arterial blood flow (24). ASL is
widely studied as an alternative method to traditional perfusion imaging techniques, which
utilize potentially nephrotoxic contrast agents. Blood-oxygenation-level-dependent (BOLD) MRI
permits non-invasive detection of tissue functionality by measuring T2* contrast generated by
deoxyhemoglobin in metabolically active tissues that are extracting and using oxygen (21).
Exogenous 1H contrast agents are engineered for several clinical applications by utilizing
a variety of targeting ligands, many of which exhibit well-characterized biochemical properties.
NMR scientists exploit a wide range of physical properties of these agents, which typically
generate contrast by modulating the local relaxation of 1H nuclei in one of the following
manners. Superparamagnetic iron oxide (SPIO) particles generate local magnetic field
inhomogeneities that can be visualized using T2*-weighted gradient echo imaging sequences
(25). Additionally, paramagnetic contrast agents containing metals such as gadolinium (Gd3+)
and manganese (Mn2+) encode agent concentration into signal intensity on T1-weighted images
(26). New techniques to image endogenous cellular proteins or exogenous agent-introduced
peptides by indirectly affecting 1H resonances include chemical exchange saturation transfer
(CEST) (27) and amide proton transfer (APT) (28,29). Finally, techniques like spin-lattice
relaxation time in the rotating frame (T1ρ) (30) have drawn attention recently, but the clinical
adoption of these newer methods still remains under investigation.
Hydrogen has been the dominant imaging nucleus of choice largely due to the numerous
mechanisms to quickly generate high-contrast clinical images with proton MRI; however, 1H
molecular and functional imaging is not without its drawbacks. All 1H-based imaging techniques
are best performed with a pre-contrast baseline scan as well as the endogenous or exogenous
4

contrast scan of interest. As such, these imaging approaches are highly susceptible to patient
motion between the two scans, which make accurate and repeatable image coregistration difficult
in the clinic. In addition, proton molecular and functional applications often suffer from the
omnipresent 1H background signal, which may hinder the unambiguous identification of sparse
molecular targets or detection of small changes in tissue functionality.

1.1.2 Non-proton MR Molecular and Functional Imaging
Non-proton MR molecular and functional imaging, on the other hand, is not plagued by
the abundant proton background signal because 1H nuclei are ignored, which might allow in
certain circumstances for the specific and sensitive detection of various disease biomarkers and
metrics of tissue functionality if the imaged nuclear spectrum is unique with no confounding
background. As an unavoidable tradeoff, however, non-proton MRI is more technically
challenging because of lower gyromagnetic ratios and inherently lower natural abundance of
detectable nuclei in patients compared to 1H MRI (31).
Table 1.1 shows several non-proton nuclei exhibiting net nuclear spin in an external
magnetic field, which are detectable with MR. Compared to 1H with a gyromagnetic ratio (γ) of
42.5 MHz/T, phosphorus (31P) and sodium (23Na) have much lower resonance frequencies (31P: γ
= 17.2 MHz/T,

23

Na: γ = 11.3 MHz/T). Since MR sensitivity is roughly proportional to γ2

according to Curie’s Law (32),

31

P and

23

Na exhibit much lower relative sensitivities when

detected with MR, calculated in Table 1.1 as 0.066 and 0.092, respectively, compared to 1H
(1.000). Despite relatively low MR sensitivity, 31P and 23Na are widely exploited as endogenous
non-proton nuclei for functional imaging in evaluating tissue metabolism and electrophysiology
because they are key components in many important organic and inorganic molecules that are
5

naturally present in animals and humans (33,34). Sodium imaging, in particular, has been
successfully utilized to enhance knee imaging in the clinic (35,36).

13

C also has a very low

relative sensitivity (0.01591), but can be hyperpolarized yielding several thousand fold increases
in sensitivity, allowing researchers to probe several key biochemical pathways including
glycolysis, the citric acid cycle, and fatty acid synthesis (37,38).
Table 1.1 NMR Properties of Proton and Non-proton Nuclei with Net Nuclear Spin
Net Nuclear
Gyromagnetic
Relative
Nucleus Abundance (%)a
Spin, I
Ratio, γ (MHz/T) Sensitivityb
1
H
99.9885
1/2
42.5775
1.00000
2
H
0.0115
1
6.5359
0.00965
31
P
100
1/2
17.2515
0.06652
23
Na
100
3/2
11.2688
0.09270
14
N
99.636
1
3.0777
0.00101
13
C
1.07
1/2
10.7084
0.01591
19
F
100
1/2
40.0776
0.83400
a
Natural abundance of the isotope in percent.
b
Sensitivity relative to 1H (1.000) assuming an equal number of nuclei and
constant temperature. Values were calculated from expression for constant
applied field (M0): 0.0076508(µ/µN)3(I+1)/I2, where I is the net nuclear spin, and
µ/µN is the nuclear magnetic moment in units of the nuclear magneton µN (39).
The gyromagnetic ratio of fluorine (19F) nuclei (40.1 MHz/T), on the other hand, is very
close to 1H (42.5 MHz/T), only 6% different (a separation of 7.6 MHz at 3T) (40). As such, 19F
spins generate favorably comparable MR signal to 1H spins with a relative sensitivity of 0.834,
or about 83% that of 1H; this is much stronger than the other non-proton imaging nuclei that are
detectable with MR. Additionally, there is essentially no

19

F background signal in the human

body (or other small animals) under physiological conditions, as seen by Table 1.2. Therefore,
19

F MR imaging, typically performed with a fluorinated contrast agent, is a promising molecular

imaging approach with the potential for extraordinary specificity. As a point of clarification, the
19

F nomenclature is used throughout to distinguish this 100% naturally-occurring (non-

radioactive) isotope of fluorine (with an atomic number of 19) from radioactive
6

18

F, which is

frequently used in fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) scans.
Finally, because

19

F atoms can be readily engineered into various organic molecules by

substituting for existing 1H atoms,

19

F MRI with appropriately functionalized contrast agents

represents a versatile imaging paradigm for quantitatively probing biomarker expression at the
molecular level (41,42).
Table 1.2 Biological Abundance of Relevant NMR Nuclei in the Human Body
Relevant
Biological
Element
NMR Nucleus
Abundancea
1
Hydrogen
H
0.63
31
Phosphorus
P
0.0024
23
Sodium
Na
0.00041
14
Nitrogen
N
0.015
13
Carbon
C
0.094
19
Fluorine
F
0.000012
a
Biological abundance is the fraction of one type
of atom in the human body, calculated from (43).
1.2 Perfluorocarbon Nanoparticle Emulsion Contrast Agents
On the forefront of this new molecular and functional imaging paradigm are the ligandtargeted perfluorocarbon (PFC) nanoparticle (NP) emulsions invented in our labs at Washington
University. This multifunctional agent (Fig. 1.1) is comprised of a lipid monolayer encapsulating
a hydrophobic perfluorocarbon core with PFCs such as perfluoro-15-crown-5-ether
(PFCE; C10F20O5) or perfluorooctyl bromide (PFOB; CF3-(CF2)6-CF2Br), which generate
nanoparticles following an emulsification process (44). These perfluorocarbons are a type of
fluorine-containing molecule derived from hydrocarbons by complete substitution of 1H with 19F
atoms. PFOB in particular has been clinically approved as a blood substitute for over 20 years
and has displayed a very good bio-safety profile because it is biologically inert and not
metabolized by human body. The nominal size of a PFC NPs is approximately 250 nm in
diameter. The half-life of PFC NPs in the blood stream is ~2-4 hours, and particles are
7

sequestered by the liver and spleen, with the perfluorocarbon component then cleared by
volatilization and exhalation from the lungs.
PFC nanoparticles have proved to be a highly adaptable delivery vehicle for targeted
molecular and functional imaging. Targeting ligands can be conjugated covalently or
noncovalently to the lipid surface to functionalize the particles. Some have termed these particles
“theranostic” agents, combining therapeutic drug payloads into the lipid monolayer along with
diagnostic imaging agents such as chelated gadolinium (Gd) (~100,000 chelates per particle),
which can be detected with T1-weighted proton (1H) imaging. Additionally, fluorine (19F)
magnetic resonance imaging (MRI) and spectroscopy (MRS) can be used to sensitively detect,
specifically identify, and directly quantify the perfluorocarbon core of these nanoparticles in a
wide variety of applications (45-50). In addition to their extensive applications in diagnostic
imaging, and due to an opportune half-life in the blood stream, PFC NPs have also been
exploited as a potential vehicle for drug delivery (6,51-53). For example, PFC nanoparticles have
been used pre-clinically to detect thrombus and plaque angiogenesis in atherosclerosis and to
deliver antiangiogenic therapy with an image-based readout of dosing efficacy (54,55).

Figure 1.1 Perfluorocarbon nanoparticle (~250 nm diameter) theranostic contrast agent can be
functionalized by inserting various targeting ligands and drug payloads into the lipid monolayer.
[Graphics courtesy of Kereos, Inc.]
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1.2.1 1H MR Molecular Imaging of Targeted PFC NP
Applications of PFC nanoparticles as a 1H contrast agent for molecular imaging have
been extensively investigated in preclinical models of cancer and cardiovascular disease,
particularly with angiogenesis targeted imaging (54). Conjugation of an RGD peptide or mimetic
to the lipid monolayer functionalizes the nanoparticles to the presence of ανβ3 integrin, offering
active targeting of these particles to neovasculature, or the formation of new blood vessels. When
Gd chelates are incorporated into the lipid surface of the particles, there is a direct inner-sphere
dipole-dipole interaction between Gd and the water molecules surrounding the biomarker sites,
leading to shorter T1 relaxation times. It has been shown that the chemical structure of the Gd
chelates affects the relaxivity of the PFC NP as a 1H contrast agent, and that chelates with longer
linker chains (e.g. DOTA-PE) enhance water relaxation more efficiently than those with shorter
chains (e.g. DOTADTPA) (56). Through T1-weighted imaging, 3D maps of angiogenesis can be
constructed to visualize angiogenesis patterns and temporal development (Fig. 1.2) (57). We
have shown that not only visualizing but also assigning values to the extent of angiogenesis
present in various tumor models is beneficial in the non-invasive characterization of
angiogenesis (55,57-62) and in monitoring (and even predicting) response to therapy (45,63,64).

Figure 1.2 Gd-bearing nanoparticles targeted to angiogenesis provide T1-weighted signal to
create 3D maps of neovasculature. 3D Neovasculature maps indicating “angiogenic switch” in
VX2 tumor. Bars indicate percent of tumor volume enhancing. [Figure reprinted with permission
from Schmieder et al. (57)]
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One series of studies by our group investigated the diagnosis and treatment of
angiogenesis

in

early-stage

atherosclerosis

with

paramagnetic

αvβ3-integrin-targeted

nanoparticles (63,65,66). It was shown that angiogenesis can be specifically targeted with these
nanoparticles and imaged in an in vivo hyperlipidemic rabbit model (Fig. 1.3). Furthermore,
using a semi-quantitative method to measure MR signal enhancement from digitally segmented
rabbit aortas, the response to a combination of antiangiogenic and cholesterol lowering therapy
(i.v. fumagillin-loaded nanoparticles plus orally-administered atorvastatin) could be monitored
and quantified over time (Figs. 1.3 & 1.4). The combination of targeted fumagillin nanoparticles
and atorvastatin synergistically sustained an antiangiogenic effect over several weeks.

Figure 1.3 (Top) Black blood image of the thoracic aorta (arrow) and segmentation of the vessel
wall (outlined in yellow) is shown for the week 0 image. The color-coded overlay of signal
enhancement (%) shows patchy areas of high angiogenesis. On the week 1 image, the signal
enhancement has clearly decreased due to the antiangiogenic effect of targeted fumagillin
treatment. (Bottom) The level of signal enhancement gradually increases at weeks 2 and 3 after
fumagillin treatment, until week 4, when the level of enhancement is practically identical to the
week 0 image. [Figure reprinted with permission from Caruthers et al. (9)]
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Figure 1.4 Cardiac magnetic resonance signal enhancement up to 8 weeks after treatment with
targeted fumagillin nanoparticles with and without oral atorvastatin. (Top) Cardiac magnetic
resonance enhancement in untreated (triangles), atorvastatin-treated (circles) and fumagillintreated animals (squares) during 8 weeks of follow-up imaging. Untreated and statin-treated
animals showed a constant level of angiogenesis in the aortic wall. Animals treated with targeted
fumagillin nanoparticles at 0 and 4 weeks showed decreased angiogenesis (*p < 0.05) after each
dose, which returned to baseline levels within 4 weeks. (Bottom) Enhancement in rabbits
receiving atorvastatin alone (triangles) or in conjunction with 1 (squares) or 2 (circles) doses of
targeted fumagillin nanoparticles. The combination of 2 fumagillin doses and statin produced a
sustained decrease in angiogenesis (*p < 0.05). [Figure reprinted with permission from Winter et
al. (67)]
In addition to Gd and ανβ3 integrin, other combinations of targeting ligands (e.g. α5β1 (57)
and Robo4 (68)) and imaging labels (e.g. manganese (69)) can be incorporated into the PFC NP
construct to investigate other preclinical disease models. Finally, although these studies show
that there is great promise for image-guided therapy using MRI, this process still inherently
yields relative measures of disease. From this research, we have experienced firsthand what
many others have also observed: that the confidence limits on image-based “quantification” can
be quite broad , particularly for MRI.
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1.2.2 19F MR Molecular Imaging of Targeted PFC NP
Targeted PFC nanoparticles actively bind to molecular biomarkers at sites of disease and
can be imaged using 19F MRI by detecting the particles’ perfluorocarbon core. It has been shown
that 19F MRI at clinical field strengths can be used to detect the sparse distribution PFC NPs at
very low concentration (picomolar) (70). Additionally,

19

F MR can be used to image PFC NPs

without conjugated 1H contrast payloads, and thus avoid potential renal damage that can be
triggered by conventional 1H contrast agents, as is the case with increased risk of nephrogenic
systemic fibrosis (NSF) associated with Gd-containing agents (71-74).
Applications of

19

F MR molecular imaging have been demonstrated in multiple

preclinical animal models of cardiovascular disease and cancer. For example, tumor
angiogenesis has been successfully imaged with 19F MRI of ανβ3 integrin-targeted PFC NP (75).
The same particle with fibrin targeting ligands has been shown to progressively bind to
atherosclerotic plaques on arterial walls. We have exploited this technology to target and image
in vitro thrombus and ruptured plaque in human endarterectomy samples (Fig. 1.5). In addition,
when combined with multiple PFCs, it can provide “multi-color” (spectral), highly specific
detection and quantification of individual targeted agents (Fig. 1.6) (49).

Figure 1.5 19F imaging and spectroscopy of crown ether nanoparticles bound to fibrin in
ruptured plaque of human carotid artery specimen. The separate 1H and 19F images (top, left) can
be combined with 19F overlaid on 1H anatomy (magnified, right). [Figure reprinted with
permission from Caruthers et al. (49)]
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Figure 1.6 Left: T1-Weighted Imaging of Fibrin Clots. (A) Paramagnetic CE nanoparticles,
bound to the clots in cross section, appear as a bright line of signal enhancement with intensity
decreasing linearly as the concentration of paramagnetic CE nanoparticle decreases (left to
right). Maximum intensity projection through the 3D data depicts the clots en face (B). Mid
Left: Volume selective 19F spectra from clots show the concentration of crown ether (CE)
decreases inversely with perfluorooctyl bromide (PFOB). Mid Right: 19F MR Imaging of PFC
NP Bound to Fibrin Clots. These three fluorine images, which have no proton “background,” are
oriented perpendicular to the clots as in A. They illustrate the fibrin-bound PFC nanoparticles of
various mixtures applied to the clots. In a broad bandwidth excitation (top), all fibrin clots
enhance brightly. Narrow bandwidth excitation allows independent visualization of the CE or
PFOB nanoparticles. Right: 19F Image-based quantification allows relative quantification of NP
concentration on clots. [Figure reprinted with permission from Caruthers et al. (49)]
Another goal of quantitative 19F MR molecular imaging of site-targeted agents is akin to
non-invasive immunohistochemistry (Fig. 1.7) (50). In this particular application,

19

F MRI

provides a quantitative readout of retained particle concentration in human endarterectomy
samples and confirms a heterogeneous accumulation of PFC NPs throughout the entire lesion
(50). Researchers have recently discovered that the porous structure of vulnerable plaques allows
plain PFC NP, without any targeting ligands, to penetrate into and accumulate within these
plaques through disrupted endothelial barriers (76). Moreover, advanced MR pulse sequences
(e.g. diffusion weighted 19F sequences (77)) and other targeting mechanisms (e.g. VCAM (15))
have been developed to extend

19

F MR molecular imaging of PFC NP to more diverse clinical

applications. Finally, recent work by Zhang et al. suggests that PFC NPs without a targeting
moiety that passively collect in the vasculature may be of use in atherosclerosis imaging (76).
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Figure 1.7 19F MRI (ex vivo) of disrupted human carotid artery endarterectomy specimen with
atherosclerotic plaque and overlying thrombus using fibrin-targeted PFC NP. Left: an optical
image of a human carotid endarterectomy sample shows moderate luminal narrowing and several
atherosclerotic lesions. Middle: A 19F projection image acquired through the entire thickness of
carotid artery sample shows high 19F signal along the lumen because of the binding of
nanoparticles to fibrin. Right: The calculated concentration map of bound nanoparticles (nM) in
the carotid sample based on 19F signal intensity in each voxel. [Figure reprinted with permission
from Morawski et al. (50)]
1.2.3 Cell Tracking using 19F MRI of PFC NP
One important application of PFC nanoparticles as a

19

F MR imaging agent is cell

tracking. Several cells types have been labeled with PFC NPs and in vivo tracking of these cells
has been confirmed in preclinical models of heart ischemia (78), lung injury (79) and organ
transplant (80), among others. Macrophages are the most widely studied cell type due to their
role in inflammatory processes, and can be labeled with PFC NPs either through in vitro
incubation or in vivo labeling in the blood stream. Macrophages internalize PFC NPs through
endocytosis and actively home to the site of disease without an observable loss of bioactivity. 19F
MRI enables noninvasive measurement of macrophage recruitment, which is believed to be an
essential indicator of the severity of inflammation (81). In addition to macrophages, stem cells
(46) and dendritic cells (82) have been labeled and quantified with 19F MRI of PFC NP. In vivo
tracking of stem cells could provide a useful imaging approach for ongoing clinical trials of
stem-cell therapy (Figure 1.8).
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Figure 1.8 Localization of PFC NPs labeled cells in mice using 19F MRI. (a) 19F MRI trafficking
of stem/progenitor cells labeled with either perfluorooctyl bromide (PFOB) (green) or
perfluoropolyether (PFPE) (red) nanoparticles. Labeled cells were locally injected into the
skeletal muscle of mouse thigh before MRI. (b)–(d) At 11.7-T field strength, 19F spectral
discrimination permits respective imaging of ∼ 1×106 PFOB-loaded cells (b) and PFPE-loaded
cells (c). The composite 19F (displayed in color) and 1H (displayed in grayscale) images (d)
reveal the location of PFOB labeled cells in the left leg and PFPE labeled cells in the right leg
(dashed line indicates 3 × 3 cm2 field of view for 19F images). [Figure reprinted with permission
from Partlow et al. (46)]
1.3 Challenges of Quantitative 19F MR Molecular Imaging
The imaging chain of a clinical MR system has many steps that may confound absolute
signal calibration (Fig. 1.9). This is especially true for non-proton nuclei, for which specialized
transmit/receive (T/R) coils must be used. For example, coil tuning and RF drive power (i.e., flip
angle) settings must be calibrated and center frequency determined for tracers such as fluorine
that are in miniscule concentrations lending little signal on which to perform these vital measures
that drive not only image quality, but ultimately accuracy of quantification. In addition, the
15

spatial distribution of imaging labels in molecular imaging is generally heterogeneous, due to the
intrinsically sparse expression pattern of pathological epitopes in tissue.

Figure 1.9 The imaging chain of a commercial MR scanner includes many steps in which
measurements and adjustments are made, from determining the power settings for accurate flip
angles, to B0 shimming, to inhomogeneities in B1 for RF transmit and receive; even during the
scan eddy currents, B0 variations, J-coupling, etc. can affect quantification outcomes.
Although interest in 19F MR molecular imaging of PFC NPs has grown significantly over
the past decade, this new imaging paradigm requires further technical advancement to overcome
these challenges to bridge the gap between laboratory and clinic. Since there is little-to-no
naturally occurring fluorine in the body, the available signal for 19F MRI is principally limited by
the administered dose of PFC NPs. Therefore, it is critical to improve imaging techniques by
enhancing sensitivity of PFC NP detection at concentrations low enough for clinical translation
(~ 1 ml/kg). Moreover, accurate quantification of PFC NPs in vivo requires image acquisition
techniques that are robust against potential field inhomogeneities associated with clinical
imaging systems (e.g. B0 and B1 field in homogeneities). Finally, unlike 1H atoms in water, 19F
atoms in perfluorocarbons experience more complicated chemical environments, which often
result in large chemical shifts and scalar coupling (J-coupling) between different line groups.

1.3.1 Signal-to-Noise Ratio
Two major factors limit the potential signal-to-noise ratio (SNR) for
number of

19

19

F MRI: the total

F imaging labels targeted to a particular site, and the small fraction of

19

F nuclear

spins that generate a detectable MR signal, governed by Boltzmann statistics and magnetic field
16

strength. Several approaches have been proposed to overcome these limitations and improve
SNR in 19F MRI. Improving the sensitivity of the radio frequency (RF) coils, which transmit and
receive the

19

F signal, is the most straightforward approach to increase SNR and subsequently

improve image quality. It is necessary to design application-specific RF coils that are suited to
particular imaging subjects, to avoid unnecessary signal loss. In addition to improved RF coils,
choosing or designing an appropriate pulse sequence (i.e., the organization and timing of RF
energy deposition, gradient application, and image formation) is also critical for optimizing 19F
imaging. Giraudeau et al. have recently shown that SNR can vary significantly (up to threefold
differences) in 19F MRI scans of fluorinated labels like PFOB depending on which sequences and
parameters (e.g. echo time, or TE) are used (83).

1.3.2 Quantitative Imaging Artifacts
19

F MRI is potentially quantitative in nature because

19

F spin density (and signal) is

linearly correlated to the deposition and resultant concentration PFC NPs at a particular site in
the body. However, in most in vivo applications, several other factors come into play that may
affect the accuracy of quantitative 19F MR measurements. For example, the measured 19F signal
might not directly reflect

19

F concentration, but instead be convolved with image acquisition

factors such as variable T1 and T2 relaxation characteristics within a perfluorocarbon molecule.
Similar to 1H MRI, 19F is also susceptible to imaging artifacts, such as motion and eddy current
artifacts, all of which can hamper image quality and can result in quantification errors (75).
Lastly, and importantly for this work,

19

F quantification suffers from field inhomogeneities

inherent to many transmit and receive RF coils. Since the concentration of PFC NPs at a site of
disease measured with 19F MR is determined by a comparison to an external standard of known
17

concentration, local differences in the B1 (RF) field between the targeted region of interest and
the location of the standard lead to errors in the quantified

19

F signal. Therefore, to achieve

accurate and reproducible 19F MRI measurements across different applications, it is necessary to
implement robust correction methods and optimized, artifact-resistant pulse sequences.

1.3.3 Chemical Shift and J-coupling
Clinically useful perfluorocarbon molecules can exhibit more complicated nuclear
magnetic resonance (NMR) spin characteristics, and hence 19F MRI properties, than do protons
with 1H MRI. As noted in Table 1.3, NMR-detectable

19

F nuclei can be observed over a much

wider spectral range (240 kHz) than 1H (1.28 kHz) or other non-proton nuclei. Chemical shift is
a term to describe how some nuclei resonate at different Larmor frequencies than others due to
differing gyromagnetic ratios (inherent to the element), or in the case of PFC molecules, to
describe how spins of the same isotope experiencing the same local magnetic field resonate at
different frequencies due to varying molecular environments (i.e. chemical bonds). Many PFC
molecules, like PFOB, contain 19F nuclei that exhibit multiple chemical shifts, which can cause
chemical shift artifacts along the readout gradient direction, and special reconstruction
algorithms are needed to correct for these artifacts (75). Moreover, these PFC 19F nuclei within
different molecular environments can have strong interactions with each other, which results in a
process called homonuclear scalar coupling, or J-coupling. J-coupling between different
chemical groups in PFC molecules causes a T2-shortening behavior in spin echo MRI (i.e. Jmodulation), which significantly reduces the detectable signal intensity for

19

F MRI. However,

once an understanding of the underlying physics of these unique NMR properties of PFC NPs is

18

achieved, the resultant artifacts can be compensated, or even taken advantage of to expand

19

F

MRI to new applications (84).
Table 1.3 NMR Spectral Ranges for Different Nuclei
Nucleus
Range (ppm)
Range (kHz at 3T)a
1
H
10
1.28
31
P
30
1.54
13
C
200
10.0
19
F
2000
240
a
Spectral ranges in kHz at 3T calculated from (85).
1.4 Dissertation Objective, Significance, and Organization
1.4.1 Objective
The objective of this thesis is to advance the state of the art for

19

F MR molecular

imaging of perfluorocarbon nanoparticle emulsion contrast agents. To achieve this objective,
three specific aims have been identified:
1. Create new tools and techniques for 19F MR molecular imaging of PFC nanoparticles.
2. Develop translatable procedures for absolute quantification of

19

F nuclei with MR

molecular imaging.
3. Evaluate the potential for clinical translation with ex vivo and in vivo preclinical
experiments.
As the quantification of these PFC NP contrast agents becomes more widely used, the
validity, accuracy, and repeatability of these metrics becomes essential to their clinical
implementation. Robust, standardized techniques are developed in this work to improve the
accuracy of quantitative MR molecular imaging, validate system performance, calibrate
measurements to ensure repeatability of these quantitative metrics, and evaluate the potential for
clinical translation. As these quantitative metrics become routine in medical imaging procedures,
these standardized calibrations and techniques are expected to be critical for accurate
19

interpretation of underlying pathophysiology. This will also impact the development of new
therapies and diagnostic techniques/agents by reducing the variability of image-based
measurements, thereby increasing the impact of the studies and reducing the overall time and
cost to translate new technologies into the clinic.

1.4.2 Significance and Innovation
In biomedical research, there is a clear and present need for repeatable, accurate
quantitative imaging as is evidenced by the recent emphasis of many interdisciplinary
committees on standardization for quantitative imaging. While true for all imaging modalities,
this is particularly true for MRI and even more so for emerging

19

F MR molecular imaging

applications where measuring biomarker concentrations accurately over time makes the
difference between success and failure – success, for example, in drug development, clinical
trials, or clinical diagnosis. Recently, NIST and others have jointly implemented traceable
phantoms to test imaging systems with standardized approaches (86), which is vital for
quantifying intra- and inter-lab variability in imaging. Characterizing system stability (or
identifying problems and having service engineers correct malfunctions) is useful for robust
signal analysis and time-resolved signal changes as is needed for first-pass dynamic contrast
enhancement (DCE). However, characterizing signal stability is not the same as calibrating
accurate derived values such as concentrations of site-targeted contrast agents, and it does not
necessarily incorporate system-specific and patient-specific settings such as power settings and
field inhomogeneity corrections. This work addresses both the validation of MR system
performance specifications and correction techniques, both prospectively and retrospectively,
with the ultimate goal of accurate, repeatable quantification in MRI. Furthermore, it expands on
20

the current efforts in the area of DCE to include imaging and spectroscopy of multiple nuclei
other than hydrogen.
The innovative aspect of this work is in the creation of novel techniques to calibrate 19F
MR molecular imaging of PFC NP emulsions where there is a low expected concentration of the
agent. Advanced dual-tuned

19

F/1H RF coils are used so that coil-specific (and, therefore,

anatomy-specific) calibrations can be performed on the 1H signal, and directly ported to the
nuclear signal of the test agent (e.g.,

19

F), regardless of its location or concentration. Fast,

automatable methods will be established to increase quantitative MR molecular imaging
accuracy, precision, and repeatability. Importantly, this capability has the potential to be
translated into user-friendly applications for clinical diagnosis and therapy monitoring. These
tools, based on high-performance, readily available clinical imaging systems, will be directly
implemented for pre-clinical and clinical trials, potentially increasing the efficiency and
effectiveness of future translational research.

1.4.3 Organization
In Chapter 2, the underlying principles behind
are explored, as well as the unique properties of

19

19

F NMR physics and image acquisition

F/1H dual-tuned RF coils. First, the NMR

physics governing all magnetically susceptible nuclear spins is reviewed, and distinctions are
drawn between 1H atoms and

19

F nuclei. Then, resultant magnetic resonance properties of

19

F

spins, such as J-coupling, are examined, along with their effect on perfluorocarbon molecules
like PFOB. Next, the theory behind image acquisition with

19

F/1H dual-tuned RF coils is

considered, which includes a coupled resonator model with appropriate impedance matching to
create two distinct resonant peaks for each nuclei. This enables truly simultaneous acquisition of
21

the 1H and 19F signals, yielding co-registered images of anatomy and function. A new dual-tuned
single-turn-solenoid RF coil is designed and constructed to open up new applications to this
simultaneous imaging. Experimental results with this new coil are then presented, including
bench tests of electromagnetic performance, as well as phantom and in vivo imaging capabilities.
Chapter 3 introduces a new pulse sequence, termed “balanced UTE-SSFP”, for highly
sensitive

19

F MR imaging of agents with complex spectra. The NMR properties of molecules

with non-proton nuclei such as PFOB are first discussed to understand their broad chemical
shifts and complex relaxation characteristics. Then, the CF2 spectral peak signatures of PFOB are
modeled, which contain 12 of the 17 available 19F nuclei in the molecule. This line group quickly
dephases and decays due to T2 relaxation, yet can be utilized if acquired quickly.
A new 3D 19F/1H pulse sequence is then designed and implemented to capture these CF2
resonances, which consists of 19F/1H RF excitation using FID acquisition at an ultra-short echo
time (UTE) and a balanced steady-state free precession (SSFP) gradient scheme with a Wongtype radial readout trajectory. The sensitivity of this new balanced UTE-SSFP pulse sequence is
compared to existing sequences with the use of an imaging phantom, and shown to have a
sensitivity twofold better than other sequences. Finally, in vivo imaging of angiogenesis-targeted
PFOB nanoparticles is demonstrated in a rabbit model of cancer on a clinical 3T scanner, to
validate the translational potential for the new pulse sequence.
In Chapter 4, a new approach to overcome challenges for accurate in vivo quantitative 19F
MR molecular imaging is presented, which includes flip angle calibration between the relevant
1

H and

19

F nuclei of interest, as well as B1-mapping compensation to offset expected RF

inhomogeneities. A disparity in the required power settings of

19

F/1H dual-tuned RF coils to

achieve optimum flip angles for the 19F and 1H nuclei is first reported and investigated. Then, an
22

approach to remediate this difference in requisite power settings is proposed and tested, which
involves a coil-specific, but spatially independent calibration ratio for each coil. This strategy
permits determination of the optimum power setting for the 19F nuclei, which are typically sparse
at least at the beginning of a typical imaging experiment, by utilizing the abundant 1H signal as a
reference.
Another challenge to accurate quantitative

19

F MRI involves inhomogeneous RF (B1)

fields produced by many RF coils. A solution is proposed that entails mapping this B1 field and
performing an image-based correction using a signal model of the acquisition technique, which is
tested in phantom and in vivo experiments in a rabbit model of cancer.
Chapter 5 examines two in vivo applications of 19F MR molecular imaging at 3T. First, a
new technique to image renal perfusion in acute kidney injury (AKI) at clinically relevant field
strengths is presented. A model of AKI is implemented in rats by ligation and occlusion of the
left renal artery, followed by reperfusion. Renal perfusion is then imaged at 3T with a

19

F/1H

dual-tuned coil after administration of PFC NPs via the tail vein. These in vivo results are
confirmed with ex vivo imaging of excised kidneys, also at 3T. Next, the impact of diet-induced
atherosclerotic plaque erosions is investigated with quantitative

19

F MRI of a hyperlipidemic

rabbit model in vivo. A method is introduced and tested that seeks to visualize nontargeted PFC
nanoparticles that accumulate passively in the intimal plaque regions of the rabbit aorta as a
consequence of endothelial erosions and vascular barrier disruption with the use of

19

F MR

molecular imaging combined with saturation bands to eliminate signal from the flowing blood
pool, which allows 19F imaging of the vessel wall itself.
Chapter 6 investigates the potential use of 19F MR molecular imaging at 3T in the clinic
with a pilot study of atherosclerosis imaging using nontargeted PFC NP in human tissue
23

specimens. Initial imaging results in a phantom and an amputated human lower limb are
presented, which show promise for the use of 19F imaging in human atherosclerosis imaging in
the future.
In Chapter 7, the major findings of the thesis are summarized and the main conclusions
that are drawn from the work are contextualized. Future directions for the work are suggested,
which include other potential clinical applications of 19F MR molecular imaging in humans.
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Chapter 2. Principles of 19F NMR Physics and Image Acquisition
with 19F/1H Dual-Tuned RF Coils

2.1 Principles of 19F NMR Physics
2.1.1 NMR Background
To further understand the principles underlying

19

F nuclear magnetic resonance (NMR)

physics, the basic concepts behind the NMR experiment will be summarized. As first theorized
by Wolfgang Pauli, certain nuclei (collection of protons and neutrons at the core of an atom)
possess an inherent angular momentum, or spin. All nuclei (or ‘spins’, which will be used here
interchangeably) with an uneven atomic number have a characteristic spin quantum number (I)
greater than zero. The spinning nature of these nuclei induces a magnetic field coincident with
the axis of spin, and can be viewed as a magnetic moment (µ) (1). These magnetic moments can
be imagined as tiny bar magnets that have the potential to interact with other magnetic fields.
Normally, the magnetic moments in a collection of nuclei will be randomly oriented, as
determined by the principles of Brownian motion. However, when a static magnetic field is
applied, these spins align either with (parallel) or against (antiparallel) the direction of the
applied field. These orientations correspond to quantum mechanical energy states, with the
number of energy levels being determined by the spin quantum number, I. As listed in Table 1.1,
nuclei with I = 1/2 (e.g. 1H, 19F, 31P, and 13C) and I = 3/2 (e.g. 23Na) have a net nuclear spin and
are detectable by NMR (2).
In the presence of an applied magnetic field (B0), the nuclear spins experience a torque,
which causes them to rotate around the axis of the applied field with a precise frequency. This
rotation, similar to the rotation of a spinning top in the presence of Earth’s gravitational field, is
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called Larmor precession. The rate of precession is dependent on the specific physical
characteristics of the isotope involved and the strength of the applied magnetic field, which is
expressed as
ω = γ*B0

[2.1]

where ω is the Larmor or resonance frequency (MHz), γ is a constant of proportionality
(gyromagnetic or magnetogyric ratio) specific to the nucleus involved, and B0 is the magnetic
field strength measured in tesla (T) (3). Larmor precession is a resonance phenomenon, meaning
a system of nuclei has a natural resonance, or frequency of oscillation, at which energy can be
most efficiently transferred to the system. With a gyromagnetic ratio of 42.58 MHz/T, 1H nuclei
precess at 127.8 MHz at 3T, while the resonance frequency of 19F nuclei (γ = 40.08 MHz/T) is
120.2 MHz (6% different). Therefore,

1

H and

19

F nuclei can be manipulated using

electromagnetic energy at those specific frequencies, which lie in the radiofrequency (RF)
spectrum (4).
When an external magnetic field is applied to a collection of nuclei, the parallel- or
antiparallel-aligning spins have a nearly identical probability of occupying either orientation at
room temperature. Luckily, however, there is a slight excess favoring the parallel (low-energy)
orientation, only about 15 parts per million (ppm) with a 1.5 T magnetic field at 300 K, governed
by the Boltzman distribution. This inequity between the two alignments contributes to the NMR
signal, yielding a bulk magnetization (M), which although rather weak, can be strengthened by
increasing the magnetic field (B0) to 3T (or to higher field strengths such at 4.7T, 7T, or 11.7T).
To obtain information about the spins, they must be perturbed or excited, to induce a
current in an RF coil by Faraday’s law of induction. This is achieved by irradiating the spin
system with an RF pulse, which is a short burst of radio frequency energy matching the Larmor
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frequency of the nuclei of interest. In a rotating frame of reference (since the spins are precessing
about the B0 field in reality), this RF excitation pulse can be represented by an additional
magnetic field (B1), which is perpendicular to B0. This B1 field rotates or ‘tips’ the initial
magnetization (M0) away from the longitudinal direction along B0 and into the transverse plane
(Mxy), at an angle that is a function of the amplitude and duration of the applied RF pulse,
expressed as
θ = γ*B1*t

[2.2]

where θ is the angle of rotation, B1 is the amplitude of the RF pulse, γ is the gyromagnetic ratio,
and t is the duration of the RF pulse. The angle of rotation, θ, is commonly referred to as the RF
flip angle (FA), and careful consideration must be made to achieve accurate flip angles for
quantitative 19F MR (as seen in Chapter 4). The energy required to tip a nucleus is defined by the
Planck equation:
E = h*ν

[2.3]

where h is Planck’s constant (6.62×10-34 J-s), and ν is the frequency of the spin. This suggests
that different energy, and hence coil power, might be required for 1H and 19F spins.
After excitation, the nuclei return to equilibrium, losing energy by emitting
electromagnetic radiation and by transferring energy to the lattice or between them. This process
is called relaxation and begins immediately after the RF pulse ends. During this relaxation
process, both the longitudinal (Mz) and transverse (Mxy) components of the net magnetization
return to their equilibrium values, when Mz is equal to the initial M0. These relaxation processes
are independent of one another, and the transverse magnetization always disappears before,
sometimes long before, the longitudinal magnetization is restored.
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The time constant that describes how Mz returns to its equilibrium value is called the
longitudinal (spin-lattice) relaxation time (T1) (Figure 2.1, left), which is described in the
following equation:
Mz = Mo(1 - e-t/T1).

[2.4]

The time constant that describes the return of the transverse magnetization (Mxy) to equilibrium
is called the transverse (spin-spin) relaxation time (T2) (Figure 2.1, right), which is described in
the following equation:
Mxy = Mxy,0*e-t/T2.

[2.5]

The spin-spin relaxation time (T2) is a result of the transfer of energy between nuclei in different
energy states, as one nucleus absorbs energy from a neighboring nucleus. These interactions
between individual spins create local magnetic field variations, which results in a gradual
dephasing of the spins causing a decay in the magnitude of the transverse component of the net
magnetization. This process is also sensitive to inhomogeneities in the applied magnetic field,
which when combined with the exponential decay of spin-spin relaxation, is referred to as T2*,
the effective transverse relaxation time (always smaller than T2).

Figure 2.1 Left: Longitudinal (spin-lattice) relaxation, described by T1 relaxation time. Right:
Transverse (spin-spin) relaxation, described by T2 relaxation time.
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In a typical NMR measurement, the application of a 90° RF pulse causes the net
magnetization vector to rotate into the transverse plane, inducing a signal in an RF detection coil
after the excitation pulse is terminates. This signal, which is a result of the free precession of the
net magnetization in the transverse plane, is called the free induction decay (FID) signal, since it
gradually decays due to the aforementioned relaxation mechanisms (Figure 2.2).

Figure 2.2 Timing diagram for a 90° RF pulse (top) followed by a free induction decay (FID)
signal (bottom) of net magnetization in the transverse plane, detectable by a RF receiver coil.
When a Fourier transform is applied to this time-domain FID, the result is a NMR
spectrum, which reveals the frequency components that make up the FID signal, typically
reported in terms of chemical shift frequency in ppm (independent of B0), rather than MHz. If
each nucleus experiences the same local magnetic field, as is the case with perfluoro-15-crown5-ether (PFCE: C10F20O5), a single observed resonance peak is observed (Figure 2.3). When
nuclei experience different local magnetic fields, as a result of their molecular structure, more
complex spectral patterns can occur, which will be discussed in upcoming sections.
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Figure 2.3 Left: Chemical structure of perfluoro-15-crown-5-ether (PFCE). 19F NMR spectrum
of PFCE, resulting in a single resonance peak since all 19F nuclei experience the same local
magnetic field.
Although there are more intricacies to nuclear magnetic resonance, this describes the
basic process needed to excite and detect nuclear spins, which governs both 1H and

19

F nuclei

alike. MRI builds upon these NMR principles to create images of the spatial distribution of these
spins, described even more briefly as follows. Gradient coils are used to change the static
magnetic field strength in all three component directions (x, y, z), in any physical orientation.
These gradient fields are used to encode spatial information into the spins by changing their
frequency and phase, since the frequency at which the nuclei precess is dependent upon field
strength (Eq. 2.1). This process generates a map of spatial frequencies, termed ‘k-space’, which
when Fourier transformed, provides an image of the distribution of the spins. Several imaging
schemes have been developed to generate MR signal, such as spin echo and gradient echo, as
well as numerous mechanisms to generate contrast, some of which will be covered in later
chapters.

2.1.2 J-coupling in 19F MR of PFC NP
In NMR spectroscopy, there are two major mechanisms of spin-spin interactions. The
strongest is the direct dipole-dipole interaction between nuclear spins, and the other is the
indirect dipole-dipole interaction between nuclei mediated through electron spins. The first type
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of interaction can affect NMR relaxation properties (e.g. T1 and T2) of nuclear spins, but it does
not lead to a split resonance peak because fast molecular tumbling usually averages out its effect.
The second type, however, generally results in a spectral peak split on the order of Hz with highresolution NMR. The indirect dipole-dipole interaction is also called J-coupling or scalar
coupling, because the coupling terms in the Hamiltonian of nuclear spins can be described as
scalars (5,6).
The chemical structure and NMR spectrum of perfluorooctyl bromide (PFOB; CF3(CF2)6-CF2Br) is shown in Figure 2.4, which exhibits a more complex spectral pattern than
PFCE. PFOB contains three distinct groups of 19F nuclei, termed ‘line groups’ since each group
results in different spectral lines, which include CF2Br, CF3, and (CF2)6. In a weak coupling
system, in which the electron cloud between two nuclear spins is not dense, J-coupling is only
related to the z component of the spins (Mz). J-coupling in most PFC molecules including PFOB
are weak couplings (e.g. the coupling between the CF3 and CF2 groups, as well as the CF2Br and
CF2 groups). The 19F nuclear spins in CF3 and the adjacent CF2 group form a typical “A2B3” Jcoupling system with a coupling constant of 12.3 Hz (7-9).

Figure 2.4 (a) Chemical structure of perfluorooctyl bromide (PFOB; CF3-(CF2)6-CF2Br). (b)
Representative MR spectrum of PFOB. The J-coupling constant between CF3 and the adjacent
CF2 group is 12.3 Hz.
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Typical full width at half maximum (FWHM) of 19F spectral peaks for in vivo MRI at 3T
is around 100 Hz, which is an order of magnitude larger than the J-coupling frequency for PFOB
for example. Therefore, instead of inducing splits in spectral peaks, J-coupling in 19F MRI causes
amplitude modulation of

19

F resonance peaks, i.e. J-modulation (6,10). J-modulation originates

from the phase difference among different peaks in a J-coupling induced multiplet (a split in a
spectral peak). As a result of J-modulation, the regular T2 decay of 19F nuclear spins is modulated
into sinusoidal oscillations, the frequency of which is dependent on the J-coupling constant. Such
an oscillating behavior dramatically shortens the apparent T2 value (T2’) and reduces the
detectable signal intensity in

19

F imaging (11). To achieve consistent quantitative

19

F MRI

measurements of PFC NP emulsions, it is important to understand the effect of J-modulation on
the PFOB-CF3 group, which will be further explored in Chapter 3.

2.2 Image Acquisition with 19F/1H Dual-Tuned RF Coils
2.2.1 Introduction
To utilize nuclei other than hydrogen, MR systems require hardware tuned to the Larmor
frequency of that nucleus. Fortunately, many 3T clinical scanners are prepared for such multinuclear transmit capabilities and simply require additional RF coils. Since the resonant
frequencies of 1H and 19F are only about 6% different (127.8 MHz and 120.2 MHz, respectively
at 3T), as seen in section 2.1, specialized RF coils can be designed to resonate at one or both
frequencies.
Many early

19

F/1H MR imaging techniques used single-frequency RF coils. A common

approach was to use tunable coils, in which the coil had to be manually tuned to either the 19F or
1

H frequency to maximize signal-to-noise ratio (SNR). There are several drawbacks to this
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approach, which requires added time to the imaging study for manual tuning, as well as the
potential for misregistration of the 19F and 1H images due to patient motion between scans (12).
Alternatively, a two-coil setup with a volume coil for 1H imaging and surface coil for

19

F

imaging introduces inherent sensitivity profile differences at the two frequencies (13). Finally,
the use of auto-tuned RF coils that can switch resonance frequencies with the assistance of an
external program entails extra complexity, a higher associated cost of the imaging system, and
the potential for tuning errors (14). The use of these single-frequency RF coils for

19

F/1H MRI

poses a number of limitations including challenges in simultaneously achieving high sensitivity
and B1 field homogeneity, and inaccurate co-registration of

19

F/1H signals due to positional

artifacts caused by coil retuning (15).
These limitations can be minimized with the use of dual-frequency, or dual-tuned, RF
coils for multinuclear MRI/MRS (16). Dual-tuned RF coils offer several benefits, among them
being user friendliness (i.e. no replacing coils between scans) without compromising sensitivity.
Truly simultaneous

19

F/1H image acquisition is possible since these coils can either transmit or

receive at both frequencies at the same time. This dual-tuned feature can also add the possibility
of calibrating the coil for tracer volumes of 19F agent based on the ubiquitous and large field of
view 1H signal from anatomy, as seen in Chapter 4.
The commonly used shunting method and multiple poles method for designing dualfrequency coils work well when the two resonant frequencies are well separated, e.g. for 1H
(42.58 MHz/T) and

13

C (10.71 MHz/T). However, such methods are not well suited for

designing 19F/1H MRI coils (17,18) because the gyromagnetic ratio of 19F (40.08 MHz/T) is too
close to that of 1H (19). Several dual-frequency strategies have been proposed for MRI/MRS at
close frequencies but each has limitations. A universal matching circuit for multi-nuclear NMR
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has been proposed (20), but it requires multi-port inputs for multi-frequency imaging.
Alternatively, several dual-frequency strategies for close and well-separated frequencies have
been proposed based on the special resonant property of a birdcage resonator (21-23). In these
designs, two crossed cages or two different modes of a birdcage are utilized to achieve the
double resonance, so these techniques are only suitable for coils with birdcage geometry, and
could lead to different B1 field profiles at the two frequencies. Recently, a novel

19

F/1H dual-

frequency solenoid coil with identical field distribution at two frequencies at 3T has been
proposed by researchers at Philips Research based on the coupled resonator model (24).
However, it remains unknown whether this concept establishes a general RF design approach for
such RF coils considering the various geometrical and electrical parameters required to fit the
needs of diverse experimental situations (25).
This work explores the coupled resonator model as a technique to design and fabricate
19

F/1H dual-tuned RF coils in diverse configurations. Due to the different impedances at the two

resonance frequencies, matching for a dual-tuned coil remains a critical challenge in practical
applications. Accordingly, the electrical properties of the coupled resonator model were
considered and a numerical calculations were executed to prove that a series capacitive matching
network is effective in matching the coupled resonator to 50 Ohm at both 19F and 1H frequencies
(18,26). A 19F/1H dual-tuned single-turn solenoid RF coil for in vivo imaging at 3T was designed
and constructed to illustrate the feasibility of the model, and tested for imaging performance.

2.2.2 Methods
The following coupled resonator model for

19

F/1H dual-tuned coils was largely

established by Hockett et al. (27) and expanded upon by Hu et al. (28).
45

2.2.2.1 Coupled Resonator Model
In the coupled resonator model, the RF sample coil is connected to a secondary inductor
and capacitor (LC) resonator with a coupling capacitor in series (Figure 2.5a). For nuclei with
close resonance frequencies, such as 1H and

19

F, the inductance of a MR sample coil can be

treated as a constant value. Following the theoretical analysis proposed by Haase et al (29), when
the secondary resonator is built with identical frequency to the sample coil, two possible
oscillating modes are formed within the circuit, namely in-phase and anti-phase modes. When
resonating in the in-phase mode, the two resonators of the circuit have equal electrical potentials,
and thus the voltage and current across the coupling capacitor always remains zero. In this case,
the coupling capacitor can be virtually removed and then the equivalent circuit of the coupled
resonator can be drawn as Figure 2.5b with the resonance frequency
[2.6]
In contrast, for the anti-phase mode, the electrical potential at both sides of the coupling
capacitor is opposite, so the voltage at the middle point of coupling capacitor remains zero. For
circuit analysis, a virtual short wire can be added between the ground and the middle point of the
coupling capacitor (Figure 2.5c), and thus it gives rise to a different resonant frequency

[2.7]
Given the gyromagnetic ratios of 1H and 19F, when

[2.8]
the two frequencies of the coupled resonator correspond to 1H and 19F frequencies, in agreement
with the analytic calculation of transfer impedance (27).
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2.2.2.2 Impedance Matching
Impedance matching is critical in dual-tuned coil design because the circuit impedance
could be different at the two resonant frequencies. For the coupled identical resonator model
(Figure 2.6d), by inverting the admittance of the parallel components, the impedance of the
coupled resonator is

[2.9]
at high frequency or in-phase mode; and

[2.10]
at low frequency or anti-phase mode.
In the dual-tuned coil design (Figure 2.5d), the coupled resonator is connected to the MR
scanner at the end of the secondary resonator in series with a capacitor matching circuit. In this
case, a small detuning of two resonators, which renders them slightly off-resonance, is able to
introduce an extra degree of freedom and compensate for the impedance difference (29). To
show the coupled resonator can always be matched to 50 Ohm with the use of appropriate values
for tuning, coupling and matching capacitors, we numerically calculated several realistic circuit
examples corresponding to various combinations of internal resistances of the sample coil and
secondary resonator. We assumed that the sample coil with an inductance 47 nH, which is equal
to the inductance of the secondary resonator, is designed to work at 3T for dual-frequency

19

F

and 1H imaging. A custom-developed program in MATLAB (MathWorks, Natick, MA, USA)
was used to seek for the appropriate values of Ct1, Ct2, Cc, and Cm to match the circuit at both
frequencies (120.2 MHz and 127.8 MHz). In the program, the preset values of Ct1, Ct2, Cc were
first calculated according to Eqs. 2.6-2.8. Then, Cm was set to be a qualitatively correct value
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according to Eqs. 2.9-2.10. Finally, a nonlinear root-seeking algorithm was carried out to vary all
the capacitances around their preset values to successively achieve impedance matching.

Figure 2.5 Schematic diagram of a coupled resonator circuit. (a) the resonator formed by
capacitor Ct2 and probe (with inductance L) is capacitively coupled, by capacitor Cc, to the
secondary resonator formed by capacitor Ct1 and inductor L. (b & c) the equivalent circuit of inphase and anti-phase mode. (d) coupled resonator is capacitively matched to 50 Ohm with Cm.
[Figure reprinted with permission from Hu et al. (30)]
2.2.2.3 Construction of Volume Coils for 19F/1H MRI at 3T
To the concept at 3T, two

19

F/1H volume coils were designed and constructed, with the

intention to be use for rat imaging. The first design was a transmit/receive single-turn solenoid
coil (8 cm diameter, 11 cm length) and the second was a similar, but larger design (11.5 cm
diameter, 14 cm length). Both coils were designed to work on a Philips 3T clinical whole-body
scanner, with 19F and 1H resonant frequencies of 120.2 MHz and 127.8 MHz, respectively.
The smaller single-turn solenoid coil was constructed with adhesive copper tape on an
acrylic tube 8 cm in diameter and 11 cm in length. The 1st resonant mode of the coil was tuned to
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the 1H frequency, 127.8 MHz (31). The secondary resonator was built with a tunable capacitor in
parallel with a custom-made inductor, which has a diameter of 4 mm and the same inductance as
the sample coil. The secondary resonator was positioned > 2 cm away from the sample coil to
minimize inductive coupling between two circuits. The coupling between the sample coil and
secondary resonators was implemented with another tunable capacitor in series with a fixed
value capacitor on the other port for the purpose of balancing. The secondary loop also was
tuned to resonance at 127.8 MHz. The value of the coupling capacitor was then adjusted to overcouple these two resonators giving rise to the second distinct frequency at 120.2 MHz (31). The
feed point for this coil (connected to a custom T/R box that interfaces with the clinical Philips
scanner) was located at the secondary resonator input and the whole circuit was matched to 50
Ohm with a tunable capacitor and fixed value capacitor. Figure 2.6 shows the circuit design as
well as an electrical simulation of the resonance properties of the coil in SPICE software.

Figure 2.6 19F/1H dual-tuned RF coil circuit. (a) Equivalent circuit diagram of two separate LCR
resonators (L1, C1, R1) and (L2, C2, R2) electrically coupled via capacitor C3. (b) Image of second
resonator circuit with coupling capacitors (C3A and C3B) and matching capacitors (C4A and
49

C4B) labeled. (c) Theoretical impedance magnitude output of a SPICE simulation of two
capacitively coupled resonators. [Figure reprinted with permission from Hockett et al. (27)]
2.2.2.4 Bench Test of Electromagnetic Performance
Laboratory bench tests were performed on a network analyzer (Hewlett Packard 8751A).
For the tuning and matching procedure, there are a total of four variable capacitors to be adjusted
for each coil. Tuning capacitors for the sample coil and secondary resonator were first adjusted
to tune the two resonators to the 1H frequency, 127.8 MHz. Then the coupling and matching
capacitors were adjusted to achieve the second

19

F frequency at 120.2 MHz, followed by

matching the dual-tuned coil impedance to 50 Ohm. The coil return loss (S11) of two coils was
tested by using a 300 ml tube filled with 1% saline to mimic the electrical load of a live rat. S21
measurements of the B1 field produced by the sample coil were performed with a 10 mm
shielded loop for signal pick up. These measurements were used to spread the capacitance of the
coupled capacitor (C1, or Ct1 in Eq. 2.6) over the length of the solenoid.

2.2.2.5 Phantom and In Vivo Imaging
Imaging performance of the smaller (8 cm diameter) coil was tested with a 300 ml bottle
of 1% saline. T1-weighted gradient echo (FFE) imaging was performed with the following
parameters were: FOV 128 mm, 256×256 matrix, slice thickness = 2 mm, voxel size =
0.5×0.5×2 mm, α = 35°, TR/TE = 20.16/6.02 ms, 25 NSA, and a scanning time of 2.1 minutes. A
signal intensity profile was calculated along the coronal direction of acquired images. RF field
homogeneity was analyzed by acquiring B1 maps with an actual flip angle imaging (AFI)
sequence with the following parameters: 128 mm FOV, 256×256 matrix, 15 2-mm slices,
0.5×0.5×2 mm resolution, α = 70°, 2.8 min scan time.
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The potential for

19

F MR molecular imaging was tested in a rat model of asthma. In

accordance with institution approved protocols, an airway inflammation model was developed in
brown Norway rats induced with injection of house dust mite (HDM) into the airway (32). After
14 days, the lungs were imaged 2h post-injection (i.v.) of 1.0 ml/kg ανβ3-integrin targeted PFOB
NP as previously described (33). To avoid signal contamination from inhaled fluorinated
anesthesia, a xylazine (10mg/kg) / ketamine (85 mg/kg) i.m. injection was used for anesthesia
induction, which was maintained with a ketamine i.v. infusion (18 mg/kg/hr). A radial 3D
balanced UTE-SSFP sequence (as described in Chapter 3) was used with the 8 cm diameter
19

F/1H dual-tuned transmit/receive solenoid coil with the following parameters: FOV = 140 mm,

matrix 643, isotropic voxel Δx = 2.19 mm, α = 30°, excitation bandwidth exBW = 5 kHz
centered on the PFOB-CF2 line group, pixel bandwidth pBW = 900 Hz, TR = 1.75 ms, TE =
90 µs (FID sampling), and a scanning time of 30 minutes.

2.2.3 Results
Photographs of dual-tuned 19F/1H solenoid coils are shown in Figure 2.7, along with the
transmit/receive box that interfaces with the clinical scanner via a BNC connector.

Figure 2.7 Photographs of single-turn solenoid RF coils. (a) Smaller coil (8 cm diameter). (b)
Larger coil (11.5 cm diameter). (c) T/R box that interfaces with clinical scanner.
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2.2.3.1 Bench Tests
The coil return loss (S11) of two coils was tested by using a 300 ml tube filled with 1%
saline to mimic the electrical load of a live rat. Although the original images could not be saved
due to older network analyzer software, Figure 2.8 shows representative log magnitude and
Smith charts of the signal loss measurements of a different phantom (50 mL saline tube)
captured with a newer network analyzer.

Figure 2.8 Simultaneous dual-frequency return loss (S11) of single-turn solenoid coil measured
using network analyzer. Return loss, better than -30 dB, is observed at both the 1H (127.8 MHz)
and 19F (120.2 MHz) resonance frequencies.
S21 measurements of the B1 field produced by the smaller solenoid coil were used to
spread the capacitance of the coupled capacitor over the length of the solenoid, as seen in Figure
2.9. This arrangement, proposed by an experience RF engineer, resulted in S21 measurements at
15 locations throughout the coil (measured as dB signal loss) that varied by no more than 2.1% at
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the 19F frequency and no more than 2.6% on the 1H frequency (as opposed to 17% and 20% at
both frequencies without spreading the capacitance out).

Figure 2.9 Arrangement of capacitors used to spread out the current in the 8 cm diameter 19F/1H
dual-tuned single-turn solenoid coil.
2.2.3.2 Phantom and In Vivo 19F/1H Imaging
Figure 2.10 shows the 1H imaging characteristics of the 8 cm diameter solenoid coil, with
a cross-sectional T1-weighted FFE image and a profile drawn through the center of the image.
Taking into account the inherent noise in this high-resolution image, it is apparent that the coil
produces a very homogeneous RF field. This is supported by the AFI B1 map (Figure 2.11), in
which the ratio of the actual/requested flip angle produced by the coil is 119.76% ± 0.03%
(standard error of the mean).
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Figure 2.10 (a) T1-weighted 1H FFE image of saline phantom using 8 cm diameter 19F/1H dualtuned solenoid coil. (b) Signal intensity profile over the distance of the phantom, as indicated.

Figure 2.11 (a) AFI B1 map of saline phantom using 8 cm diameter 19F/1H dual-tuned solenoid
coil (119.76% ± 0.03% actual/requested flip angle). (b) AFI intensity profile over the distance of
the phantom, as indicated.
Figure 2.12 displays the in vivo imaging capability of the 8 cm

19

F/1H dual-tuned

solenoid coil. When tuned to better than -30dB signal loss on both frequencies, the coil enables
high-quality 1H and 19F images (Fig. 2.13a&b, respective) of ανβ3-integrin targeted PFC NP in a
rat lung model of asthma using a truly simultaneous 19F/1H balanced UTE-SSFP sequence.
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Figure 2.12 1H (a) and 19F (b) images of a rat lung model of asthma using simultaneous 19F/1H
imaging of ανβ3-integrin targeted PFC NP.
2.2.4 Discussion
This work described a generalized strategy for designing and fabricating

19

F/1H dual-

tuned coils based on the coupled resonator approach. The single-turn solenoid coil tested here
with phantom and in vivo imaging experiments on a clinical 3T scanner was shown to produce
high-quality 1H and

19

F images, with sensitive detection of PFC NP. A unique feature of this

design is that it preserves the B1 field homogeneity of the RF coil at both resonance frequencies.
By eliminating the effects of patient motion between 1H and
design enables direct co-registration of

19

19

F image acquisition, this coil

F and 1H images for localizing delivered

19

F PFC NP

agents.
The coupled resonator paradigm for designing dual-tuned coils may be limited when
imaging nuclei with well-separated frequencies. In this case, the frequency-dependent inductance
of the sample coil will be significantly different at the two working frequencies. It will be
difficult to construct a small copper loop inductor that has the same frequency-dependent
inductance as the sample coil, and thus it will hinder the equivalence of the sample coil and the
secondary resonator. The “in-phase” and “anti-phase” modes, as described previously, will not
form as expected. Therefore, the strategy of using the coupled resonator model to fabricate a
55

dual-frequency MRI coil is only suitable for close Larmor frequencies, e.g.
13

19

F/1H or possibly

C/23Na.

2.2.5 Conclusion
As the installed-base clinical scanners with multinuclear capabilities continues to grow,
this coupled resonator dual-tuned coil design may help facilitate ultimate clinical adoption of
simultaneous 19F/1H MR molecular imaging techniques.
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Chapter 3. Balanced UTE-SSFP for 19F MR Imaging of Complex
Spectra
3.1 Introduction
Magnetic resonance methods are emerging for functional and quantitative physiological
detection of nuclei other than hydrogen (1), all of which require specific optimization of imaging
techniques and hardware. Sodium imaging has been successfully utilized in knee imaging (2,3),
while hyperpolarized and non-hyperpolarized gases are also proving useful in lung imaging (4,5).
Concomitant development of novel contrast agents has created possibilities for imaging a variety
of nuclei, for example recently the multiple molecular species of liquid perfluorocarbons in
nanoparticle formulations (6). Targeted perfluorocarbon (PFC) imaging agents profess the
opportunity to target and quantify markers of disease in cardiovascular, oncological, and other
applications. Some of the early work involved targeted cells, both in vitro and in vivo, and
tracking the cells by detecting their unique fluorine signatures (7,8). Other techniques involve the
accumulation of tracers by macrophages, which can then be imaged by their fluorine signals (9).
Still other agents have been shown to target pathological tissues to detect and quantify biomarker
concentration, as exemplified by ανβ3-integrin targeting of angiogenesis in cancer and
atherosclerosis (10-13). Moreover, commercial interest in such agents by pharmaceutical
companies has been demonstrated by recent reports of angiogenesis targeting and imaging with
19

F compounds (14).
19

F magnetic resonance spectroscopy and imaging offer several advantages over

hydrogen-based methods, including highly specific detection due to an absence of biological
background signal, and the ability to quantify local concentration of fluorinated agents (15). As
such, 19F MRI bears a high potential for molecular imaging allowing the direct quantification of
61
	
  

	
  

targeted PFC nanoparticle (NP) emulsions (16). Previous in vivo reports of PFC NP have
exploited the single resonance peak of perfluoro-15-crown-5-ether (PFCE; C10F20O5) (17).
However, perfluorooctyl bromide (PFOB; CF3-(CF2)6-CF2Br) is a more clinically-relevant NP
core with a better understood human safety profile (18), but it exhibits a more complex spectrum
with seven

19

F resonance peaks and multiple relaxation conditions (19). Furthermore, although

gadolinium (Gd) chelates have been shown to enhance the

19

F signal through T1 shortening

(20,21), the absence of Gd is more attractive from a translational point of view, due to the risk of
nephrogenic systemic fibrosis (NSF) associated with Gd agents (22-24).
While true for any non-proton contrast agent, fluorine-based agent detection incurs
several inherent technical challenges. Many agents have short apparent T2’ relaxation times,
which can vary across their spectral peaks (25). In addition, rich spectra and large chemical shifts
(CS) like those found in PFOB add significant complexity that challenges optimal signal
detection. Several methods have been developed to manage CS artifacts and cope with short
apparent T2’ times encountered in multinuclear MR. Mastropietro et al. have recently optimized
the sequence parameters of fast spin-echo (FSE/RARE) for some

19

F reporters, but different

fluorinated agents will likely require individual parameter tuning based on their spectral
properties and the local environment (26). Single 19F resonances, such as the CF3 line group in
PFOB, have been utilized (27), but significant tradeoffs in SNR efficiency remain when other
lines are ignored. Others have investigated chemical species separation using an iterative
decomposition with echo asymmetry and least-squares estimation (IDEAL), which requires a
complex δB0 correction (28,29). In an effort to capture signal from all PFOB spins, echo-time
encoding with relaxation correction has been implemented (30), in addition to pulse-phase
encoding (PPE) (31). Lastly, chemical shift independent techniques like fluorine ultrafast turbo
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spectroscopic imaging (F-uTSI) have been employed to register the entire 19F spectrum (32,33),
albeit with a significant acquisition time penalty.
Perhaps the most straightforward method to image complex

19

F spin systems in

consideration of destructive phase interference is to acquire the signal before the spins dephase,
as in ultra-short echo time (UTE) imaging (34). Line dephasing occurs over time, when the spin
species of an imaging agent are subject to individual Larmor precession according to their
respective chemical shift, which can lead to destructive signal overlay. In addition, transverse
relaxation prevents a full signal recovery at later time points. Short echo time sequences like
UTE offer the ability to capture these spins before line dephasing occurs, and thus retain their
NMR signal to potentially boost the SNR (35). Balanced steady-state free precession (SSFP) is a
technique in which each gradient pulse within one TR is compensated by a gradient pulse with
an opposite polarity, resulting in a single, rephased magnetization vector (36). As such, the SSFP
sequence retains much of the initial magnetization (M0), which yields a steady state MR signal
with high achievable SNR. Furthermore, the elimination of gradient-induced dephasing within
each TR would further counteract the line dephasing that occurs in complex spectra.
Accordingly, a new technique—dual-frequency 19F/1H UTE with a balanced SSFP pulse
sequence and 3D radial readout—was developed to permit highly sensitive detection of multiresonant imaging labels like PFOB without the need for Gd. It was hypothesized that the 19F/1H
UTE-SSFP pulse sequence with 3D radial acquisition would image PFOB NP with higher
detection sensitivity than tradition Cartesian k-space filled 19F sequences including gradient echo
(GRE), balanced SSFP, and fast spin echo (FSE) on the PFOB (CF2)6 group, as well as the PFOB
CF3 peak sampled with FSE. The preclinical objective of this study was to image angiogenesis in
a rabbit adenocarcinoma model with the simultaneous
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targeted PFOB nanoparticles with and without Gd to establish the feasibility of high sensitivity
MR molecular imaging of Gd-free, fluorine-based, clinically relevant contrast agents. Such a
technique will be critical for the clinical implementation of targeted molecular MRI.

3.2 Methods
3.2.1 Pulse Sequence Design
To optimize pulse sequence parameters, the spectral characteristics and NMR relaxation
properties of the PFOB molecule were analyzed (Figure 3.1). In addition to single 19F resonance
peaks for the PFOB CF2Br and CF3 groups, the CF2 line group contains twelve of the seventeen
fluorine nuclei, which result in five spectral components (at 3T: 0, ± 100 Hz, ± 500 Hz). As
shown in Figure 3.1b, the five proximate chemical shift (CS) components of the CF2 group,
represented by different spin vectors (β, γ, δ, ε, ζ, ρ), lead to destructive signal overlay at larger
echo times (e.g., 2.8 ms). However, all CS components remain within a phase range of ± 90° for
0.5 ms and are not yet significantly affected by the apparent T2’ relaxation (10 ms) (37). Using a
UTE-SSFP sequence with an echo time of 100 µs, a typical gradient performance of 200 Tm-1s-1
and a pixel bandwidth of 1 kHz, the FID readout requires ~0.6 ms resulting in a spatial resolution
of ~1 mm, which is well suited for the detection and quantification of targeted PFOB-NP. During
a fast FID readout, as in the balanced UTE-SSFP technique presented here, the relative signal
from the CF2 resonances remains above 60%, which cannot be recovered at later echo times.
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Figure 3.1 a: Perfluorooctyl bromide (PFOB: CF3-(CF2)6-CF2Br) 19F spectrum. b: All chemical
shift components of PFOB CF2 line group (β, γ, δ, ε, ζ, ρ) remain within a phase range of ± 90°
for 0.5 ms. c: 19F signal evolution of the (CF2)6 line group with and without apparent T2’
relaxation. During a fast FID readout as in the balanced UTE-SSFP technique, the relative signal
remains above 60%, which cannot be recovered for later echo times. [Figure reprinted from
Goette, et al. In press]
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A simultaneous 3D 19F/1H balanced UTE-SSFP pulse sequence was designed to capture
these CF2 resonances (Fig. 3.2). The sequence consists of simultaneous 19F/1H RF excitation (38)
and subsequent FID acquisition at an ultra-short echo time, using balanced gradients with a
Wong-type (39) radial readout trajectory. The UTE excitation and FID acquisition are designed
to acquire the

19

F signal before dephasing develops, while the balanced SSFP gradients are

designed to exploit the achievable high steady-state signal and to synergistically reduce
extraneous line dephasing. The simultaneous 1H excitation and acquisition is not necessarily part
of the sensitive 19F detection sequence but is beneficial for an efficient scan time and precise colocalization of fluorine signals with the underlying anatomy.

Figure 3.2 A simultaneous 3D 19F/1H balanced UTE-SSFP pulse sequence, consisting of
simultaneous 19F/1H RF excitation and subsequent FID acquisition at an ultra-short echo time,
using balanced gradients (m, mr) with a Wong-type (39) radial readout trajectory. Logical
gradient lobes (m, mr) are superimposed into a single continuous gradient waveform when
executed on the physical gradient coils. [Figure reprinted from Goette et al. In press]
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3.2.2 Phantom Imaging Experiments
The study was performed on a 3T clinical whole-body scanner (Achieva, Philips
Healthcare, The Netherlands), outfitted with a dual
resonant

19

19

F/1H spectrometer system (38). Dual-

F/1H RF coils were used, which can either transmit or receive at both frequencies

simultaneously (40).
Feasibility of balanced UTE-SSFP imaging was demonstrated in a phantom experiment
using a bottle containing a flask (inner diameter 38 mm) filled with perfluorooctyl bromide (CF3(CF2)6-CF2Br) surrounded by water. The simultaneous 19F/1H 3D balanced UTE-SSFP sequence
with Wong-type radial readout was implemented using a

19

F/1H dual-tuned transmit/receive

small-animal solenoid coil (inner diameter 7 cm) with the following parameters: FOV = 128 mm,
matrix 1283, isotropic voxel Δx = 1.0 mm, α = 30°, excitation bandwidth exBW = 5 kHz
centered on the PFOB-CF2 line group, pixel bandwidth pBW = 900 Hz, TR = 2.1 ms, TE = 90 µs
(FID sampling), Texp = 71 s.
The effect of the balanced gradient scheme on sequence performance was determined by
acquiring an additional 3D radial UTE gradient-echo (GRE) data set using identical acquisition
parameters (α = 30°), but without balanced gradients (TR = 3.6 ms). Additionally, a 3D radial
UTE GRE sequence at Ernst angle (α = 5°) was tested, following determination of the T1
relaxation time for the PFOB-CF2 line group (840 ms) (41). The GRE sequences do not apply RF
spoiling, such that the signal may be optimized at α > αE, depending on the actual T2 relaxation
time. Slab-selective (10 mm) serial spectroscopic acquisitions were employed on both the CF2
and CF3 line groups of the PFOB phantom to determine T1 using inversion recovery, FID
sampling, and variable TI delay (10-2810 ms in 200 ms steps), as well as apparent T2’ using
spin-echo TE delay (13-53 ms in 2 ms steps for CF2 and 13-583 ms in 30 ms steps for CF3).
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For comparison to existing techniques, 3D gradient-echo (GRE), balanced SSFP, and fast
spin-echo (FSE) sequences with Cartesian k-space sampling were used with identical FOV (128
mm) and spatial resolution (1×1×1 mm3 voxels). An elliptical restriction of the two phase
encoding dimensions was applied to the 3D Cartesian sampling such that the actually sampled
portion of k-space was similar to the radial sampling in the UTE and balanced UTE-SSFP
sequences. Other gradient-echo imaging parameters included α = 30°, exBW = 5 kHz, pBW =
900 Hz, TR/TE = 4.8/2.1 ms, Texp = 104 s. Balanced SSFP was used with α = 30°, exBW =
5 kHz, pBW = 900 Hz, TR/TE = 4.2/2.1 ms, Texp = 89 s. Fast spin-echo parameters included α =
90°, FSE acceleration factor 116, pBW = 660 Hz, exBW = 2830 Hz, TR/TE = 4000/7.4 ms, Texp
= 1032 s. For further comparison to alternative line selection methods (27), a fast spin-echo
sequence was performed on the CF3 line using the same FSE parameters.

3.2.3 Sensitivity Comparisons
In the phantom imaging experiments, sensitivity was selected as a metric to compare
imaging techniques to take into account SNR as well as scan time for each sequence. Detection
sensitivity (S) was defined and calculated as:

S=

SNR

[3.1]

mol/voxel × Texp

where SNR is the achieved signal-to-noise ratio, Texp is the duration of the sequence, and
(mol/voxel) is the amount of PFOB agent within an imaging voxel. To assess the signal-to-noise
ratio, 19F signal I0 was measured on the magnitude image in a rectangular region of interest (ROI)
within the PFOB phantom. Noise was determined from the standard deviations σ[Re] and σ[Im]
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in a rectangular ROI at the border of real and imaginary images. An area separated from the
phantom and free of coherent background signal in any sequence type (e.g., by signal blurring)
was chosen. From this data, SNR was calculated as:

SNR =

I0
σ Re 2 +σ Im 2

[3.2]

3.2.4 In Vivo Imaging Experiment
For in vivo validation, targeted PFOB NPs were imaged in rabbit models of cancer and
atherosclerosis. All animal procedures were approved by the Animal Studies Committee of
Washington University in St. Louis.
Oncological applications of this sequence were investigated with Male New Zealand
White rabbits (~2 kg, n = 4) that were implanted in the popliteal fossa of the left hind leg with 23 mm VX2 adenocarcinoma tumors (National Cancer Institute, MD), which grew to ~15 mm
within 2 weeks (42). Imaging was performed 3h post-injection of 1.0 ml/kg ανβ3-integrin
targeted NP with PFOB core as previously described (43), either with or without Gd-DTPAbisoleate incorporated on the outer layer. To avoid signal contamination from inhaled fluorinated
anesthesia, a xylazine (10mg/kg) / ketamine (85 mg/kg) i.m. injection was used for anesthesia
induction, which was maintained with a ketamine i.v. infusion (18 mg/kg/hr). The radial 3D
balanced UTE-SSFP sequence was implemented using a

19

F/1H dual-tuned transmit/receive

surface coil (7×12 cm) with the following parameters: FOV = 140 mm, matrix 643, isotropic
voxel Δx = 2.19 mm, α = 30°, excitation bandwidth exBW = 5 kHz centered on the PFOB-CF2
line group, pixel bandwidth pBW = 900 Hz, TR = 1.75 ms, TE = 90 µs (FID sampling), and a
scanning time of 30 minutes.
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Additionally, cardiovascular applications of this sequence were investigated by inducing
atherosclerosis in Male New Zealand White rabbits, which were fed high cholesterol chow for 20
weeks. Imaging was performed 2h post-injection of 1.0 ml/kg of the ανβ3-targeted PFOB-NP.
The simultaneous 19F/1H balanced UTE-SSFP sequence with 3D radial readout was acquired at
six time points post-injection with the following parameters: FOV = 140mm, matrix 1123,
isotropic voxel Δx = 1.25mm, α = 30°, excitation bandwidth exBW = 9kHz, pixel bandwidth
pBW = 900Hz, TR = 2.0ms, TE = 100µs (FID sampling), and a total scan time of 28 minutes.
For the in vivo experiments, the radial k-space data were reconstructed at full resolution
for the 1H component, and a lower resolution with higher signal-to-noise for the 19F component.
The latter was achieved by applying a flat k-space weighting to the data outside a radius
corresponding to a percentage of the fully sampled sphere in k-space (20% of the Nyquist radius
for the adenocarcinoma-implanted rabbits; 7% of the Nyquist radius for the atherosclerotic
rabbits) and using the usual quadratic weighting for the center of k-space (44). Since most signal
intensity is located close to the center of k-space, flat weighting of higher k-values does not lead
to signal losses but reduces noise amplification in high k-values and thus further improves SNR
at the expense of spatial resolution.

3.3 Results
The balanced UTE-SSFP pulse sequence was successfully implemented and run on a 3T
whole-body scanner. Figure 3.3 shows a magnitude image of the phantom bottle containing
PFOB, acquired with the balanced UTE-SSFP sequence, with ROI drawn to show locations for
measuring 19F signal (I0), and the location of the noise calculation that was performed on the real
and imaginary images to calculate SNR as per Eq. 3.2.
	
  

70

	
  

Figure 3.3 Magnitude 19F image of sensitivity imaging phantom, showing PFOB signal acquired
with balanced UTE-SSFP sequence. ROI show locations of 19F signal (I0) [middle], and noise
[right] used for SNR calculations. [Figure reprinted from Goette et al. In press]
Table 3.1 summarizes the observed sensitivity for the investigated sequence types, as
calculated by Eq. 3.1. With S = 51 µmolPFOB-1min-1/2, the proposed balanced UTE-SSFP
technique demonstrates a sensitivity of at least twice that of other sequence types. 3D UTE GRE
sequences without balanced gradients at α = 30° and α = 5° (Ernst angle) exhibit substantially
lower sensitivities (20 and 8 µmolPFOB-1min-1/2, respectively). Analysis of the spectroscopic series
data revealed a T1 of 840±40 ms and 1000±40 ms for the CF2 and CF3 peaks, respectively, and
an apparent T2’ of 10±1 ms and 230±10 ms for the CF2 and CF3 peaks, respectively.
The second-best sequence is balanced SSFP with a Cartesian k-space trajectory
(23 µmolPFOB-1min-1/2), demonstrating the value of using balanced gradients for the detection of
perfluorocarbons. For the CF2 group, the proximate CS components lead to destructive signal
overlay at larger echo times (e.g., 2.8 ms), which are difficult to separate with line selection
techniques. The 3D gradient-echo acquisition demonstrates this signal loss (TE = 2.1 ms), with a
measured sensitivity of 12 µmolPFOB-1min-1/2. Fast spin-echo techniques are typically highly SNR
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efficient, but are not optimal for perfluorocarbons like PFOB (16 µmolPFOB-1min-1/2), since the
achievable echo times (here TE = 4.7 ms) do not allow full signal combination of the CF2-group.
Selecting the CF3 group is possible, but this choice only uses 3 of the 17 available fluorine nuclei,
which resulted in lowered sensitivity (7 µmolPFOB-1min-1/2).
Table 3.1 Sensitivity of 19F MR Acquisition Techniques

Sensitivity
(µmolPFOB-1min-1/2)a
CF3
Cartesian fast spin-echo
7
Cartesian gradient-echo (α=30º)
12
Cartesian fast spin-echo
16
Cartesian balanced SSFP (α=30º)
23
(CF2)6
Radial UTE gradient-echo (α=5º)b
8
Radial UTE gradient-echo (α=30º)
20
Radial balanced UTE-SSFP (α=30º)
51
-1/2
a
-1
Sensitivity measured as S = SNR×(mol/voxel) ×Texp , where SNR is the achieved
signal-to-noise ratio, Texp the sequence duration, and (mol/voxel) the amount of
PFOB agent within an imaging voxel.
b
Ernst angle calculated as α = cos-1(exp-(TR/T1)), where TR = 3.6 ms, and T1 was
measured at 840 ms.
PFOB Line(s)

19

F Sequence

In vivo imaging of angiogenesis-targeted PFOB nanoparticles was successful in a rabbit
model of cancer, demonstrating heterogeneous areas of neovasculature at the tumor rim (Fig.
3.4a&d, arrows) as expected in this established VX2 tumor model. On 1H images, the bound
nanoparticles that carry Gd give rise to T1-based signal enhancement (Fig. 3.4d), whereas the
Gd-free NP are invisible in 1H MRI (Fig. 3.4a). The fluorinated core of this PFOB NP emulsion
was imaged with the simultaneous

19

F/1H balanced UTE-SSFP sequence using parameters that

were tested in the phantom experiment. For PFOB-NP both without and with Gd, the resultant
19

F signal clearly elucidates the heterogeneous distribution of detected NP (Fig. 3.4b&e,

respectively), which is overlaid on 1H anatomy to demonstrate anatomical co-localization (Fig.
3.4c&f).
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Figure 3.4 Molecular imaging of ανβ3-integrin targeted NP on VX2 tumors (arrows) in rabbits
by 19F MRI. Gd-free (a,b,c) or Gd-containing (d,e,f) NP with a perfluorooctyl bromide (PFOB)
core were used and imaged with a novel balanced UTE-SSFP based 3D radial sequence. 1H
images show T1-based enhancement only with Gd NP (d), while the 19F signal is clearly detected
in both cases (b&e). Image overlays (c&f) demonstrate the anatomical co-localization. [Figure
reprinted from Goette et al. In press]
In vivo imaging of atherosclerosis with angiogenesis-targeted PFOB nanoparticles was
also successful using the 19F/1H balanced UTE-SSFP sequence. Figure 3.5a shows an example of
the proton image quality in a selected slice at the aorta, which is robust against motion due to the
simultaneous 3D radial acquisition. The isotropic voxels allow multi-planar reformatting for
visualizing anatomy and prescribing ROIs for analyzing the directly corresponding 19F NP signal.
In this example, ανβ3-targeted PFOB-NP were detected in the aorta ROI (Fig. 3.5b) in
concentrations ranging from 10 to 16 mM.

	
  

73

	
  

Figure 3.5 Simultaneous 19F/1H molecular imaging of angiogenesis targeted perfluorooctyl
bromide nanoparticles in a rabbit model of atherosclerosis using 3D radial balanced UTE-SSFP.
Proton image (a) with 1.25 mm isotropic voxels show anatomy, upon which 19F image can be
overlaid (b). The ROI in (b) is surrounding the aorta, which has a diameter of about 5 mm. The
19
F overlay within the aortic region is in green, and extra-aortic 19F signal is blue.
3.4 Discussion
This study introduced and tested a novel pulse sequence,

19

F/1H balanced UTE-SSFP

with 3D radial readout, for the imaging of non-proton nuclei with complex spectra. The sequence
was implemented on a clinical 3T scanner to enable detection of multi-resonant fluorine imaging
labels like PFOB with high sensitivity as compared to traditional techniques. A majority of the
PFOB fluorine nuclei (12 of 17) are located in the CF2 resonances, which are distributed over a
wide chemical shift range. Within the 90 µs echo time of the balanced UTE-SSFP sequence
however, we showed that dephasing does not lead to destructive superposition of these
resonances, which serves to maximize the obtained signal. The signal gain by constructive
addition of all CF2 lines over-compensates the loss in SNR-efficiency imposed by 3D radial
sampling (25%) and the FID readout, which requires twice the number of k-space lines, since all
start at kx,y,z = 0 (45). Point-spread function effects of the k-space sampling might change the
actually sampled voxel volume and thus influence the sensitivity comparison. Because of the
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chosen elliptical restriction of the phase encoding in Cartesian sampling, these effects were
considered to be negligible.
The sensitivity obtained for the spoiled gradient-echo sequence using radial UTE readout
allows separating the contributions of short echo times (reduced dephasing) and the use of
balanced gradients. Without the spoiler gradients used in GRE, TR is decreased for the balanced
case, which accounts for about 30% of the observed sensitivity gain (20 to 51 µmolPFOB-1min-1/2).
Thus, the application of balanced gradients can be estimated to result in a twofold sensitivity
gain for the CF2 line group. This result is similar to the sensitivity gain found by introducing
balanced gradients in the Cartesian CF2 acquisitions (12 to 23 µmolPFOB-1min-1/2).
The experimental results show a substantial, 2.5-fold increase in the UTE GRE signal
from Ernst angle (αE = 5° for T1 = 840 ms) to α = 30°. According to GRE signal theory without
RF spoiling (see e.g. (46), Eq. 4.22, TR = 4.8 ms, T1 = 840 ms) this is only expected for species
with actual T2 values much larger than the measured apparent T2’ of 10 ms (consistent with (25)).
At an estimated actual T2 of 110 ms, the GRE signal theory predicts a 2.5-fold signal increase
when changing from α = 5° to 30°, while the signal gain would be lower at any significantly
shorter T2. The apparent T2’, as measured by multiple spin echo times, is known to be strongly
influenced and shortened by homonuclear J-coupling (25). Recent work by Jacoby et al. (19)
demonstrates this point, measuring the T2 of emulsified PFOB, which varies over the CF2 peaks
from 75 to 80 ms; however, the narrow band excitation and refocusing used by this group likely
does not completely eliminate the effects of J-coupling, leading to a measured T2 that is still
shorter than the actual T2 of the CF2 peaks. Additionally, Giraudeau et al. (27) have shown
exceptionally high actual T2 values of 400 to 900 ms for the PFOB CF3 group when using
narrow band refocussing in spin-echo to reduce J-coupling effects. Interestingly, the T2 is shown
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to increase at shorter echo time, which is hypothesized to be due to a reduced influence of the
coupled (quantum) state on relaxation at shorter TE. Furthermore, the actual T2, and hence signal,
depends on whether the PFOB is neat, encapsulated, or bound to a target (19,27). Our results
suggest that an actual T2 value (and not apparent T2’) is required to correctly model the signal
gain obtained by flip angle optimization and by applying balanced gradients.
To further elucidate the cause for this observed signal increase in the balanced UTESSFP sequence, signal models (MT denoting the modeled transverse magnetization) were
generated for GRE (N-FFE, FAST, GRASS, FISP), balanced SSFP (B-FFE, R-FFE, true FISP),
as well as RF spoiled GRE (T1-FFE, FLASH, SPGR) according to Vlaardingerbroek et al. (46)
as follows:
E1 = e

-TR

-TR

E2 = e

T1

[3.3]

T2

[3.4]

GRE (N-FFE, FAST, GRASS, FISP) [Eq. 4.22 from (46)]:
MT = sin α cos α +1 * 1+ cos α -A
A = 1-E1 *E22 + cos α * E22 -E1

A2 +B2 +1

1-E1

[3.5]
[3.6]

B = 1+ cos α *E2

[3.7]

Balanced SSFP (B-FFE, R-FFE, true FISP) [Eq. 4.24 from (46)]:
MT = sin α * 1-E1

1-E1 cos α -E2 * E1 - cos α

[3.8]

RF-spoiled GRE (T1-FFE, FLASH, SPGR) [Eq. 4.16 from (46)]:
MT = sin α ∗ 1-E1

	
  

1-E1 cos α

[3.9]
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Figure 3.6 shows the result of this signal modeling, with transverse magnetization (MT)
plotted as a function of flip angle (α, degrees), using the measured T1 of the PFOB CF2 line
group (840 ms) and the estimated actual T2 of 110 ms. A 50% gain in signal is observed in the
balanced SSFP (R-FFE) signal model at α = 30°, compared to the gradient echo signal (GRE, NFFE). With RF-spoiled GRE (T1-FFE), the maximum signal occurs at the Ernst angle as
expected; however, GRE remains rather T2-dependent, so the Ernst angle does not apply for this
signal model. For the steady-state signal in both GRE and balanced SSFP, only the actual T2
decay (not apparent T2’) is relevant for the signal build-up. This is because J-coupling only leads
to destructive interference in the sum of the splitted components, but not to an accelerated
relaxation of the transverse magnetization of each component.
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Figure 3.6 Modeled steady-state gradient echo signal as a function of flip angle (α) for balanced
SSFP (“R-FFE”, red line), GRE (“N-FFE”, blue line), and RF-spoiled GRE (“T1-FFE”, green
line) using an estimated actual T2 of 110 ms.
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The flip angle choice of α = 30° in the present study was suggested by a previous study
using a Cartesian GRE sequence on fibrin target bound PFOB nanoparticles (47), which showed
a signal optimum at α = 30° to 35° and a signal decay for larger flip angles. While a sequence
comparison at a fixed flip angle, as performed in this study, is clearly demonstrating the
respective signal gain by using ultra short echo time and balanced gradients, the individual
optimum flip angle for each sequence type was not explored. Inserting the estimated actual T2 of
110 ms (neat PFOB) into the signal theory for balanced SSFP (Eq. 3.8) allows one to estimate an
optimum flip angle and to predict the signal gain by introducing balanced gradients as compared
to GRE. According to this theory, balanced gradients at α = 30° resulted in a 50% signal increase
and the signal maximum would be expected at 40°, as seen in Figure 3.6. The actually observed
signal gain (twofold) does not match this calculation, likely due to the fact that the actual T2 is
not well known and may depend on sequence parameters. A more detailed analysis of the actual
T2 relaxation of the PFOB CF2 line group for neat and encapsulated PFOB forms would provide
important information to optimize balanced UTE-SSFP sequences (e.g. flip angle choice). A flip
angle of 30° could be a practical choice for in vivo applications of the proposed balanced UTESSFP technique for PFOB loaded nanoparticles, where T2 relaxation may be faster due to
restricted motion. The current parameter choice in balanced UTE-SSFP led to the successful
observation of ανβ3-integrin targeted NP with a PFOB core, as shown in the VX2 tumor model.
Although the focus of this work was on PFOB nanoparticle emulsions, the balanced
UTE-SSFP technique offers several benefits for multinuclear imaging of many non-proton
agents, such as perfluorodecalin (C10F18) or perfluorooctane (C8F18) (19,48). This pulse sequence
is optimal for contrast agents with a short apparent T2’ relaxation, due to the ultra-short echo
time and fast FID acquisition. Agents bound to molecular targets may be of particular interest,
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since they exhibit reduced T2’ relaxation due to decreased molecular motion (47). In addition, the
balanced SSFP approach yields high SNR, in particular for imaging labels with characteristically
unfavorable long T1 relaxation for gradient-echo methods due to M0 saturation, as is the case
with PFOB. Although T1-shortening of Gd has been shown to be beneficial in fluorine imaging,
the balanced UTE sequence provides high signal even for PFOB-NP without Gd with a T1 of
about 1 second. Moreover, the balanced gradient technique is advantageous for the detection of
agents with complex spectra due to the elimination of extraneous gradient-induced line
dephasing. The combination of these two schemes offers a flexible pulse sequence for complex
resonant structures, which can be customized to the agent of choice by altering offset frequency
and excitation bandwidth to dial in a particular line group.
As shown in this study, the proposed balanced UTE-SSFP sequence can be combined
with simultaneous dual-nuclei techniques for efficient anatomical localization and quantitative
calibration of the non-proton signal. Once the complex spectral signal is acquired with this
sequence, the 3D radially-filled k-space data can be directly reconstructed, and does not require
post-processing as would chemical shift imaging. As an added benefit, the 3D radial data set
offers the potential for multi-resolution reconstruction, allowing analysis of the 19F and 1H data
at different spatial resolution (44). Note that the reconstruction of the

19

F data at a lower

resolution and higher SNR was only performed for the in vivo experiment to demonstrate this
capability in sparse molecular imaging environments; all

19

F data were reconstructed at full

resolution in the phantom experiments when comparing balanced UTE-SSFP to existing
techniques. Finally, this unique simultaneously acquired data provides an opportunity for motion
correction of the non-proton signal with temporal sub-sampling of the 1H data (38). Although a
prototype dual 19F/1H spectrometer system was used for simultaneous acquisition in this study, a
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similar 19F UTE-SSFP sequence was also successfully implemented on a standard multinuclear
scanner platform.
In this study, the balanced UTE-SSFP sequence was shown to be more sensitive than
traditional acquisition techniques in the context of multinuclear imaging of contrast agents with
short T2 and complex spectra. However, some agents may not require advanced line combination,
such as those with single resonance peaks. Application of the balanced UTE-SSFP sequence for
such agents might result in decreased SNR-efficiency due to the 3D radial sampling and FID
readout. In addition, the bandwidth of this technique may not be large enough to cover all lines
of an agent, because of the large chemical shifts found in 19F. Thus, a particular line group must
be selected within a bandwidth of approximately 1-2 kHz, for an appropriate spatial resolution of
the 3D radial readout with standard gradient systems. While advantageous for the detection of
PFOB since a majority of

19

F spins are found in the CF2 line group covering ~1 kHz, this

bandwidth restriction may be a limitation for other chemical species. Another obstacle for this
sequence was found in the classic balanced SSFP banding artifacts that were observed in both
the 1H and 19F components in some images, but these were reduced by shortening TR and can be
moved out of the region of interest by adjusting the offset frequency for the balanced signal.

3.5 Conclusion
Radial 3D balanced UTE-SSFP is a robust pulse sequence that yields high SNR, with
detection sensitivity more than two-fold improved over more traditional techniques, while also
alleviating problems associated with extended longitudinal relaxation times, short apparent T2’,
and complex spectral properties of imaging agents. This technique was demonstrated for dualfrequency
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F/1H MRI on a clinical scanner that allows highly sensitive in vivo detection of
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multi-resonant imaging labels like perfluorooctyl bromide, which could play a central role in
human translation of 19F MR-based targeted molecular imaging. The synergistic combination of
an optimized imaging technique and a gadolinium-free, biocompatible contrast agent should
facilitate translation into clinical use.
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Chapter 4. Improved Quantitative 19F MR Molecular Imaging with
Flip Angle Calibration and B1-Mapping Compensation

4.1 Introduction
MR molecular imaging with the use of ligand-targeted contrast agents has proven capable
of noninvasively detecting the presence of cellular indicators of biological processes for many
classes of pathologies (1-4). Common exogenous contrast mechanisms have employed either
paramagnetic or superparamagnetic readouts based on the composition of the core materials of
nanoparticulate agents that function by altering the local relaxation properties of protons in T1 or
T2/T2* weighted images to reveal local changes in MRI contrast indicative of a binding event (5).
Of the paramagnetic agents, one of the first to become useful for a broad range of imaging
applications was a perfluorocarbon core nanoparticle decorated with several hundred thousand
gadolinium atoms with the use of conventional chelating chemistries, and a smaller population of
molecular targeting ligands (e.g., antibodies, small molecules, peptides, etc.) covalently coupled
into a surrounding lipid/surfactant monolayer (6-9). Further model-based efforts have been
pursued to quantify these sparse binding events in attempts to compute the concentrations of the
targeted epitopes (10). Yet all of these approaches that rely on indirect readouts of binding
through altered proton relaxation suffer from high background proton signals, susceptibility
artifacts (11), potential toxicities of the contrast agent itself (12,13), and most importantly, the
need for both pre- and post-contrast images to accurately delineate changes in local contrast
(14,15).
For some time, it has been appreciated that the ability to create local MRI contrast based
on detection of alternative nuclei such as fluorine (19F) might offer a direct and quantifiable
89

readout of molecular binding events (16-18). Fluorine exhibits well-known advantages of being a
high signal nucleus with a natural abundance of its stable isotope, favorable toxicity profiles, a
convenient gyromagnetic ratio close to that of protons (D: ~6%) (19), and a unique spectral
signature with no detectable background at clinical field strengths (20). However, clinical
development of this approach has been slowed by the need to deposit sufficient concentrations of
the contrast material within a voxel to yield a detectable signal, and by the lack of imaging
hardware and software (e.g., coils, multinuclear spectrometers, pulse sequences, etc.). Over the
past 15 years, our own efforts in 19F contrast agent development and imaging at 1.5 and 3T with
the assistance of commercial partners have yielded translatable solutions to many of these
imaging hardware needs (21,22), while simultaneously validating the utility of the PFC-core
nanoparticle agents as targetable molecular imaging probes (23-25).
However, for

19

F MRI to mature as a truly robust whole body detection approach for

quantifying molecular binding events noninvasively, additional obstacles must be overcome.
Although 19F MRI is potentially quantitative in nature because

19

F spin density (and signal) is

linearly correlated to the deposition and resultant concentration PFC NPs at a particular site in
the body (17), the imaging chain of a clinical MR system comprises many steps that can
confound absolute signal calibration, even when specialized transmit/receive (T/R) coils are used
(26). Coil tuning and RF drive power (i.e., flip angle) settings must be calibrated and center
frequency determined for 19F tracers that are in miniscule concentrations lending little signal on
which to perform these measures that drive not only image quality, but ultimately accuracy. 19F
MRI also is susceptible to imaging artifacts, such as motion, partial volume, and eddy currents,
all of which can degrade image quality and produce quantification errors (21). Lastly, B1-field
inhomogeneities that are inherent to many transmit and receive RF coils must be accounted for
90

(27,28). Because the concentration of PFC NPs within a voxel is determined by a comparison to
an external standard of known

19

F concentration, local differences in the B1 field between the

targeted region of interest and the location of the standard may lead to errors in the quantified 19F
signal.
This study pursues additional measures that are intended to improve accuracy for in vivo
quantitative 19F MR molecular imaging, including flip angle calibration (between the relevant 1H
and

19

F nuclei of interest), and B1 field mapping compensation to offset anticipated RF

inhomogeneities. Herein, we hypothesize that the RF power settings that are typically optimized
for 1H might also be used to determine the correct RF power settings for
with

19

19

F signals acquired

F/1H dual-tuned RF coils. Furthermore, a solution to overcome inhomogeneities

associated with RF coils is proposed that relies on mapping the B1 field on the 1H signal and then
performing an image-based correction to the 19F and 1H data by signal modeling, which is then
tested in phantom and in vivo experiments in a cancer model in rabbits for tumor angiogenesis
targeting.

4.2 Methods
4.2.1 Magnetic Resonance Spectroscopy
All magnetic resonance spectroscopy and imaging data were acquired on a 3T clinical
whole-body scanner (Achieva, Philips Healthcare, The Netherlands) with a dual

19

F/1H

spectrometer system (21). Dual-resonant 19F/1H RF coils were used, which can either transmit or
receive at both resonance frequencies simultaneously (29). Three dual-tuned coils were used for
the MRS experiment including a single loop rectangular surface coil (7×12 cm, Philips
Healthcare, The Netherlands), a custom-built semi-cylindrical coil (13 cm diameter, 15 cm
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length), and a custom-built single-turn solenoid coil (11.5 cm diameter, 14 cm length) (Fig. 4.1).
Before each MRS experiment, the

19

F/1H coils were tuned to resonate at both the fluorine and

hydrogen frequencies (120.1 and 127.7 MHz, respectively at 3T) on a network analyzer
(National Instruments, Austin, TX, USA) at -30 dB signal loss or better.

Figure 4.1 19F/1H dual-tuned RF coils. (a) Single loop rectangular surface coil (7×12 cm, Philips
Healthcare, Best, The Netherlands). (b) Custom-built 6-element semi-cylindrical coil (15 cm
diameter), and (c) single-turn solenoid coil (11.5 cm diameter, 14 cm length). [Figure reprinted
from Goette, et al. In review]
4.2.2 PFC NP Formulation and Phantom Setup
A nontargeted perfluoro-15-crown-5-ether (PFCE: C10F20O5) NP emulsion was prepared
as previously published (30), which was composed of 20% (v/v) PFCE (Exfluor Research Corp.,
Round Rock, TX, USA), 2.0% (w/v) surfactant commixture, and 1.7% (w/v) glycerin, with water
comprising the remaining balance. An MRS point source phantom was created by filling a 1 mL
clear glass shell vial (6 mm inner diameter, National Scientific, Rockwood, TN, USA) with 50
mM PFCE NP emulsion in 2% agar (0.2 mL volume, 5 mm height in vial), with 2% agar
comprising the rest of the volume. The phantom was positioned in a 1 L beaker filled with 275
mL 1.0% saline using a custom-built holder allowing translational movement in two directions
(± 18 mm) at three different heights (9 mm, 15 mm, and 27 mm) above the surface and semicylindrical coils, and within the solenoid coil.
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4.2.3 Power Setting Optimization and Flip Angle Calibration
Flip angle sweep experiments were performed on the

19

F and

1

H frequencies

independently to determine optimal RF output settings for flip angle calibration. Slice-selective
spectroscopic echo sampling was first performed on the

19

F signal as a single series, sweeping

the flip angle setting from 10° to 210° in 10°-increments with the following parameters: 10 mm
slice, 8 kHz excitation BW centered on single PFCE peak, TR/TE = 2000/2.6 ms, 4 NSA, scan
time 4 min, automated power optimization preparation phase turned off. Peak power settings
were adjusted according to the offset between real and requested 90° pulse, and the sequence was
repeated in an iterative fashion until the optimal power setting was achieved, denoted by a
maximum spectral height at the requested 90° pulse (Fig. 4.2a).
After acquiring a similar data set at this same power setting on the 1H channel for
comparison, the process was repeated at the 1H frequency until an optimal power setting was
achieved, which was then compared to the 19F setting. This experiment was repeated in triplicate
with the phantom located at 15 distinct locations for each coil, with replicates occurring on
separate days after detuning and retuning the coils.
Optimized RF power settings for the 19F and 1H nuclei were depicted with a 3D ball plot
in MATLAB (MathWorks, Natick, MA), with both spherical radius and color representing peak
power (W) for each nucleus, averaged over each replicate. A ratio of 19F/1H peak power at each
phantom location is also visualized with a ball plot, and a global average of 19F/1H peak power
from all locations is reported for each RF coil, termed flip angle calibration ratio.
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4.2.4 MRI Phantom Setup and B1-Mapping Compensation
Two fluorine-containing phantoms were created to design and test a B1-mapping
compensation technique to correct for RF inhomogeneities in

19

F MRI with

19

F/1H dual-tuned

coils. A discrete sample phantom was made with two 5 mL glass vials (inner diameter 15 mm)
filled with 1.0 M sodium fluoride (NaF) in 2% agar, aligned 2 cm apart in 200 mL bottle of 1.0%
saline. A homogeneous

19

F phantom consisted of a 300 mL glass bottle (inner diameter 6 cm)

filled with 1.0 M NaF in 2% agar.
A simultaneous 19F/1H 2D balanced FFE (bFFE) imaging sequence was used to generate
transverse

19

F and 1H images of the phantoms, with identical parameters as follows: 140 mm

FOV, matrix 64×64, 4 mm slice thickness, 2.18×2.18×4 mm resolution, exBW = 4 kHz centered
on the single NaF peak, pBW = 500 Hz, α = 25°, TR/TE = 3.64/1.82 ms, NSA = 1000, 3.8 min
scan time. The B1 field was mapped using an actual flip angle imaging (AFI) sequence with the
following parameters for both phantoms: 140 mm FOV, matrix 64×64, 13 4-mm slices,
2.18×2.18×4 mm resolution, α = 70°, TR/TE = 13.43/2.23 ms, 1.0 min scan time.
To correct for RF inhomogeneities present in the simultaneous

19

F/1H bFFE image

acquisition, the sequence was modeled following rephased gradient echo theory as per Eq. 4.24
in Vlaardingerbroek et al. (31) as
M T = M 0 sin α nom E2

1− E1
1− E1E2 − (E1 − E2 )cos α nom

,

[4.1]
E1,2 = e

where αnom is the nominal flip angle and

−TR/T1,2

. From this signal model, a calibration factor

(ρ) can be defined as
ρ = sin(AFI ∗ α nom )

1− E1
1− E1E2 − (E1 − E2 )cos(AFI ∗ α nom )

,

[4.2]
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where AFI represents the voxel values from the B1 map (αrequested/αnominal). A spatially dependent
calibration mask was calculated from Eq. 4.2 in MATLAB and used to compensate the 1H and
19

F signal intensities of the bFFE molecular imaging sequence by dividing each image by ρ, on a

voxel-by-voxel basis.

4.2.5 In Vivo 19F MRI Experiment
An in vivo 19F MR imaging study was performed at 3T with the 19F/1H dual-tuned single
loop surface coil previously mentioned (7×12 cm). In accordance with institution-approved
protocols, New Zealand White Rabbits (2 kg) (n = 3) were implanted with a VX2
adenocarcinoma tumor (2-3 cm) in the hind leg (30), and allowed to grow for two weeks prior to
imaging to achieve a tumor size ~ 15 mm. An ανβ3-integrin-targeted PFCE NP emulsion (20
vol%) was injected intravenously and allowed to circulate 3 hours before imaging. To avoid
signal contamination from inhaled fluorinated anesthesia, a ketamine (85 mg/kg) / xylazine
(10mg/kg) i.m. injection was used for anesthesia induction, which was maintained with a
ketamine i.v. infusion (18 mg/kg/hr).
A simultaneous 19F/1H balanced UTE-SSFP imaging sequence with Wong-type 3D radial
readout trajectory (32) was used with the following parameters: 140 mm FOV, matrix 963,
isotropic voxel Δx = 1.46 mm, exBW = 4 kHz centered on the PFCE peak, pBW = 400 Hz, α =
30°, TR/TE = 2.32/0.13 ms, NSA = 56, 35 min scan time. For this in vivo experiment, the radial
k-space data were reconstructed at full resolution for the 1H component and a lower resolution
with higher signal-to-noise for the

19

F component. The latter was achieved by applying flat k-

space weighting to the data outside a radius corresponding to 23% of the fully sampled sphere in
k-space (23% of the Nyquist radius) and using the usual quadratic weighting for the center of k95

space (33,34). After anatomical colocalization of

19

F signal was confirmed with the

simultaneously acquired 1H image, a high-resolution gradient echo 1H image was used to display
the overlaid 19F signal with the following parameters: FOV = 128×128 mm, matrix = 256×256,
slice thickness = 4 mm, voxel size = 0.5×0.5×4 mm, α = 35°, TR/TE = 25.16/7.02 ms, 23 NSA,
and a scanning time of 2.5 minutes.
The B1 field was mapped with an AFI sequence with the following parameters: 140 mm
FOV, 96×96 matrix, 15 1.46-mm slices, 1.46×1.46×1.46 mm resolution, α = 70°, TR/TE =
16.0/2.93 ms, 1.9 min scan time. Because balanced UTE-SSFP follows the same balanced
gradient echo theory as the bFFE sequence in the phantom experiment, a spatially dependent
calibration mask (ρ) was calculated from Eq. 4.2 in MATLAB and used to compensate the 1H
and

19

F signal intensities on a voxel-by-voxel basis. Importantly, the same correction scheme

was performed on the imaging slice that contained the fluorine standard (150 mM19F PFCE NP in
agar) to which the in vivo bound PFC NP 19F signal was compared for quantification.

4.2.6 Statistical Analysis
MR spectroscopy and imaging data were analyzed with analysis of variance (ANOVA) or
student t-tests as appropriate with MATLAB. For all statistical tests, p < 0.05 denotes statistical
significance. Standard errors of the mean are reported for MRS and MRI measurements, and
used to display error bars. Measures of 19F image homogeneity were calculated as a root-meansquare value over all 19F signal-containing voxels.
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4.3 Results
4.3.1 Power Setting Optimization and Flip Angle Calibration
Power settings were optimized for 19F and 1H nuclei, such that a requested 90° flip angle
yielded a maximum spectral height in FA sweep measurements of a PFC NP point source
phantom. Figure 4.2 shows a representative FA sweep that was optimized for 19F (top), and the
resultant 1H FA sweep (bottom) using the same power setting (peak power = 122.9 W), which
obviously was too high for 1H, yielding a maximum 1H spectral height at 20°.

Figure 4.2 Representative flip angle sweep (10°-210°) on 19F nucleus (top) and 1H nucleus
(bottom) using the same power setting (peak power = 122.9 W) with a 19F/1H dual-tuned surface
coil indicating correct power settings for 19F, but too high for 1H. [Figure reprinted from Goette,
et al. In review]
Power settings for 19F and 1H nuclei are depicted in a 3D ball plot (Fig. 4.3), in which the
spherical radius and color correspond to the requested peak power (W) for a point source PFCE
97

NP phantom at 15 distinct locations in the FOV of the surface coil, averaged over three
replicates. These plots exemplify the need for higher power settings to accurately measure
sources farther away from a surface coil, as well as the obvious difference in optimal power
settings between

19

F and 1H nuclei. However, a ratio of optimum

19

F/1H power requirements

yields a spatially independent calibration value for the surface coil (1.48 ± 0.06).

Figure 4.3 3D Ball plot representation of optimized RF power settings (peak power, W) for 19F
(a) and 1H (b) nuclei using a 19F/1H dual-tuned surface coil and a point source phantom of PFCE
NP emulsion. (c) Ratio of optimum 19F/1H power setting yields a spatially independent
calibration value (1.48 ± 0.06 for surface coil). [Figure reprinted from Goette, et al. In review]
Figure 4.4 displays the MRS phantom data for all three

19

F/1H dual-tuned coils, with

averaged measurements from all five locations at each height (9, 15, 27 mm). Optimized

19

F

peak power was significantly different than was the 1H power requirement at each height for
each coil (p < 0.05 in all cases). Taking a ratio of 19F/1H power settings for the semi-cylindrical
coil yielded a calibration value of 1.71 ± 0.02, and 1.92 ± 0.03 for the single-turn solenoid coil.

Figure 4.4 Power settings (peak power, W) needed to optimize 90° flip angle for 19F and 1H
signals from point source phantom at 9 mm, 15 mm, and 27 mm above 19F/1H dual-tuned surface
coil (a), semi-cylindrical coil (b), and within single-turn solenoid coil (c). [Figure reprinted from
Goette, et al. In review]
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4.3.2 B1-Mapping Compensation in Phantom Experiments
Figure 4.5 demonstrates a technique for B1-mapping compensation of 19F MRI using the
1

H signal in a phantom containing two vials of 1.0 M NaF in agar, imaged with a simultaneous

19

F/1H bFFE sequence and a

(Fig. 4.5a) and

19

19

F/1H dual-tuned surface coil. Before correction, the

19

F image

F/1H overlay image (Fig. 4.5b) exhibit the effects of the inhomogeneous RF

field produced by the surface coil. Mean signal intensity in the vial closest to the coil was 2537 ±
176 arbitrary units (a.u.), while the 19F signal from the identical vial 2 cm further from the coil
was 66.0% lower (863 ± 40, p < 0.001). The B1-field was mapped using the 1H signal with actual
flip angle imaging (% actual/requested FA) (Fig. 5c), and input into Eq. 4.2 to create a correction
ratio (Fig. 4.5d). This factor was used to correct both 19F and 1H signal intensities, as displayed
in Figure 5e&f. After correction, the mean signal intensity in the vial closest to the coil (2621 ±
156 a.u.) was not significantly different (p = 0.85) than that in the vial farther from the coil (2681
± 129 a.u.).

Figure 4.5 19F MRI of phantom with two vials of 1.0 M NaF in agar using a simultaneous 19F/1H
bFFE sequence and a 19F/1H dual-tuned surface coil. Before correction, 19F image (a) and 19F/1H
overlay image (b) illustrate the inhomogeneous RF field produced by the surface coil, resulting
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in a mean signal intensity of 2537 ± 31 a.u. and 863 ± 7 a.u. in each vial. 1H B1-field was
mapped with actual flip angle imaging (% actual/requested FA) (c), and input into bFFE signal
model to create a correction factor (d), which was used to compensate 19F and 1H signal
intensities. The corrected 19F image (e) and 19F/1H overlay image (f) demonstrate the imagebased compensation technique, resulting in a mean signal intensity of 2621 ± 27 a.u. and 2681 ±
23 a.u. in each vial. [Figure reprinted from Goette, et al. In review]
Figure 4.6 shows the results of the one-way ANOVA analysis of the phantom before and after
correction.

Figure 4.6 One-way ANOVA analysis of the 19F signal intensity from phantom of two PFC NP
vials (1: closer to coil; 2: farther away) before (left) and after (right) B1-mapping compensation.
Figure 4.7 shows the B1-field compensation applied to a homogeneous phantom of 1.0 M
NaF in 2% agar. Before correction, the

19

F (Fig. 4.7a) and

19

F/1H overlay images (Fig. 4.7b)

display the inhomogeneity of the surface coil, with a mean signal intensity of 1145 ± 35 and a
RMS value of 1320. B1-mapping compensation with AFI and calculated correction ratio (Fig.
4.7c&d), yielded a more homogeneous corrected 19F image (Fig. 4.7e), as measured by a mean
signal intensity of 2332 ± 29 and a RMS value of 1157.
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Figure 4.7 19F MRI of a homogeneous phantom (1.0 M NaF in 2% agar) imaged with a
simultaneous 19F/1H bFFE sequence and a 19F/1H dual-tuned surface coil. Before correction, the
19
F image (a) and 19F/1H overlay image (b) illustrate the inhomogeneous RF field produced by
the surface coil. 1H B1-field was mapped with actual flip angle imaging (% actual/requested FA)
(c), and input into bFFE signal model to create correction ratio (d), which was used to correct 19F
and 1H signal intensities. The corrected 19F image (e) and 19F/1H overlay image (f) demonstrate
the image-based compensation technique. [Figure reprinted from Goette, et al. In review]
4.3.3 In Vivo 19F MRI Experiment
PFC NP targeted to the tumor neovasculature provided a highly localized

19

expected (Fig. 4.8, tumor enhancement circled in red). In the uncorrected

F signal as
19

F image

superimposed on a high-resolution 1H image of the rabbit anatomy (Fig. 4.8a), the concentration
of PFC NP localized to the tumor was measured at 20.0 ± 0.12 mM19F, when compared to an
external standard (150 mM19F). By using the AFI B1-field map and calibration mask (Fig.
4.8b&c) to compensate the

19

F image for inhomogeneities introduced by the RF surface coil,

local targeted PFC NP was calculated at 25.5 ± 0.10 mM19F, or a 27.5% increase (p < 0.05).
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Figure 4.8 B1-mapping compensation of in vivo cancer model in rabbit with the use of ανβ3integrin-targeted PFC NP nanoparticles captured by 19F MRI with a 19F/1H dual-tuned surface
coil (located at image right). In the uncorrected 19F image overlaid on the high-resolution 1H
image (a), PFC NP concentration was quantified as 20.0 ± 0.12 mM19F, compared to an external
standard of known concentration (150 mM19F). Illustrated are: B1-field mapping with AFI (%
actual/requested FA) (b) and calibration mask calculated from a balanced UTE-SSFP signal
model (c). In the corrected 19F image overlaid on the high-resolution 1H image, PFC NP
concentration was quantified as 25.5 ± 0.10 mM19F. [Figure reprinted from Goette, et al. In
review]
4.4 Discussion
This study describes a strategy to more accurately quantify sparse
targeted perfluorocarbon nanoparticle emulsions by means of

19

19

F MR signals from

F flip angle calibration that

utilizes the abundant 1H signal, and a 1H image-based B1-mapping correction to the 19F and 1H
images. The requisite peak power to achieve a requested flip angle for

19

F and 1H nuclei was

shown to be different for three 19F/1H dual-tuned RF coils. However, a ratio of the two optimized
power settings results in a spatially independent calibration ratio that was unique to each coil.
Once established, the coil-dependent calibration ratio can be used to set the power settings for
19

F imaging based on the 1H signal for all imaging with the coil, regardless of location within the

field of view. For sparse fluorine signals as would be expected in clinical MR molecular
imaging, power settings and calibrations cannot be performed easily on the

19

F nuclei a priori.

However, 19F flip angle calibration can be performed based on the rich 1H signal by multiplying
the 1H-derived power settings by the calibration ratio before any
introduced.

102

19

F contrast agent is even

This work also demonstrated the utility of an image-based B1-mapping compensation to
correct signal intensities for simultaneously acquired 1H and 19F images. The deleterious effects
of coil inhomogeneities on quantitative

19

F MRI were demonstrated in a phantom experiment

where two significantly different signal intensities were demonstrated for identical fluorine
samples with the use of a

19

F/1H dual-tuned surface coil. However, the proposed B1-mapping

compensation technique corrected the signal intensity for both the

19

F and 1H images, thereby

removing the effects of the inhomogeneous RF field. This method was further tested in a
homogeneous fluorine phantom, which corrected for the characteristic signal drop-off observed
with surface coils, as a consequence of employing the proposed B1 correction technique to
improve 19F image homogeneity. Finally, the preclinical utility of this correction technique was
tested with an in vivo cancer model of the B1 compensation technique that apparently improved
the measurement accuracy of bound ανβ3-integrin-targeted PFC NP with
Unfortunately, independent direct comparison of

19

19

F imaging.

F signals to tissue levels of PFC NP is

technically complex due to extraction difficulties and PFC volatility, but given the clear benefit
of the compensations in phantoms, we propose that the derived answers will be more satisfactory
following correction.
This study was performed with

19

F/1H dual-tuned coils, which consist of the same coil

elements, and hence generate the same B1 field for both

19

F and 1H nuclei (29). The observed

difference in requisite power settings between the two nuclei demonstrates the effective
difference in detection sensitivity of these dual-resonant coils, because they are electrically tuned
in the same manner for both nuclei. However, this difference is consistent for each coil, and
allows for the determination of a specific coil-dependent calibration ratio. Notably, this property
is likely unique to dual-resonant coils, which cannot be replicated with single-tuned coils or
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other double-frequency coils with significantly different geometry between 19F and 1H resonator
elements. On the other hand, although the B1 correction technique using 1H-derived B1 maps to
correct

19

F and 1H images also benefits from the use of dual-tuned RF coils, this technique

should apply to single-tuned coils if the B1 fields for the two nuclei are the same. In the future,
additional testing with both dual-tuned and single-tuned coils would be valuable to determine
translatability of this technique to such coils.

4.5 Conclusion
In conclusion, this study devised and tested a new approach to overcome certain
challenges for accurate in vivo quantitative

19

F MR molecular imaging, which comprises a

combination of flip angle calibration between 1H and 19F nuclei, and B1-mapping compensation
to offset RF inhomogeneities. Correction techniques such as this one should facilitate improved
accuracy and repeatability of measurements of non-proton molecular imaging agents used in
preclinical and clinical trials at routine field strengths.
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Chapter 5. Novel In Vivo Applications of 19F MR Molecular Imaging at 3T

The third aim of this thesis was to evaluate the potential for clinical translation with ex
vivo and in vivo preclinical experiments. To successfully translate the techniques presented in
this work, and the work of many other molecular imaging scientists, into the clinic to help
diagnose and treat diseases in humans, there must be thorough testing and validation with
controlled animal experiments. In addition to the oncological applications of improved

19

F MR

molecular imaging of ανβ3-integrin-targeted PFC NPs presented in Chapter 4, two more
potentially translatable applications are presented here: renal perfusion imaging and
atherosclerotic plaque imaging. Importantly, translation of both of these applications to humans
requires their implementation at clinical field strengths, so a clinical 3T MR scanner is used
instead of a small animal scanner at a higher field strength.

5.1 Imaging Renal Perfusion in Acute Kidney Injury at 3T
5.1.1 Introduction
Acute kidney injury (AKI) affects a significant portion of hospitalized patients in the
United States and has an attendant mortality of up to 76.8% (1). AKI is characterized by reduced
renal blood flow and abnormal intrarenal oxygenation as a consequence of inflammatory
signaling molecules that affect tubular function and renal microcirculation (2). Noninvasive
imaging of intrarenal perfusion in AKI patients could be useful for diagnosing the extent of
damage, as well as monitoring response to therapy. However, in many cases the use of contrast
agents is restricted due to associated renal toxicity (3), and no specific agents have been
approved to target the well-defined molecular mechanisms involved in AKI (4).
110

While arterial spin labeling (ASL) has been reported as a noninvasive technique to
measure renal perfusion in AKI (5), there are challenges to accurate perfusion quantification
such as variations in blood T1 (6), which is often present in AKI subjects with abnormal
intrarenal oxygenation. Recently, perfluorocarbon (PFC) nanoparticle (NP) emulsions have been
evaluated as a promising nontoxic agent for MR molecular imaging of renal damage and
perfusion on an 11.7T Varian small animal MR scanner (7). Furthermore, 19F MR using a 19F/1H
dual-tuned RF coil has been utilized to directly image and quantify the fluorinated core of PFC
NP emulsions at clinical field strengths (8), where the signal is directly proportional to local
blood volume. In this study, we investigated the imaging of renal perfusion using simultaneous
19

F/1H MRI of PFC NPs in an ischemia/reperfusion rat model of AKI at 3T.

5.1.2 Methods
All protocols, including animal handling, surgery, and treatment, as well as MRI
procedures were approved by the Animal Studies Committee of Washington University in St.
Louis. Under anesthesia with ketamine (85 mg/kg) and xylazine (13 mg/kg), adult male Sprague
Dawley rats (n = 6) (Harlan Laboratories, USA) underwent a surgical procedure to induce
unilateral warm ischemia, followed by reperfusion. Following a laparotomy to expose the
vasculature of the left kidney, the left renal artery was ligated and either permanently occluded (n
= 2) or occluded for 45 min followed by reperfusion (n = 2). Age-matched normal rats were
included as controls (n = 2). Animal body temperature was maintained at 37°C using a small
animal heating system. The surgical wound was then closed in layers, after which the animal
recovered and was returned to its cage. Following recovery for 24 hr, the injured kidney and
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contralateral control kidney were imaged either in vivo or excised, fixed in 10% formalin, and
imaged ex vivo.
A nontargeted perfluoro-15-crown-5-ether (PFCE: C10F20O5) nanoparticle emulsion (20
vol%) was prepared as previously published (9), and injected i.v. into the tail vein (3 ml/kg) 5
min before imaging or excision. MR data were acquired on a 3T clinical whole-body scanner
(Achieva, Philips Healthcare, Best, The Netherlands) with a dual 19F/1H spectrometer system and
a dual-tuned transmit/receive solenoid RF coil (7 cm diameter for in vivo; 4 cm diameter for ex
vivo). Following

19

F/1H flip angel calibration (as seen in Chapter 4), a simultaneous 2D

19

F/1H

balanced FFE (bFFE) imaging sequence was used with the following parameters: 140 mm FOV
(cross-sectional images: 64 mm FOV), matrix 64×64, 3 mm slice thickness, exBW = 4 kHz
centered on the single PFCE peak, pBW = 500 Hz, α = 25°, TR/TE = 4.198/2.10 ms, NSA = 500,
5 min scan time. The low-resolution 1H images (not shown) were used to confirm kidney
visualization and anatomical coregistration. For display, higher-resolution 1H images were
acquired with a 2D TSE sequence and similar geometry: 140 mm FOV (cross-sectional image:
64 mm FOV), matrix 256×256, 3 mm slice thickness, TR/TE = 500/27.8 ms, NSA = 4, 2 min
scan time. The B1 field was mapped (on 1H) using an actual flip angle imaging (AFI) sequence
with geometry matching the cross-sectional images: 64 mm FOV, matrix 64×64, 7 3-mm slices,
1×1×3 mm resolution, α = 70°, 40 s scan time. Renal perfusion in the cortex and medulla was
measured in the injured kidney by quantification of local PFC NP concentration via comparison
to an external standard of known PFCE concentration (comprising 150 mM19F PFCE NP in 2%
agar).

112

5.1.3 Results
Figure 5.1 demonstrates the feasibility to image renal perfusion in vivo with 19F MRI at
3T. Fig. 5.1a shows the anatomical 1H image along the long-axis of the permanently occluded
left kidney and the normally perfused right kidney. Functional 19F image (Fig. 5.1b) shows the
blood pool PFCE signal in the same animal with kidney locations outlined in red (arrow: injured
left kidney). The coregistered 1H (gray scale, Fig. 5.1c) and

19

F (color coded in green) image

shows no PFCE signal, reflecting no perfusion to the occluded left kidney, but normal perfusion
to the right kidney. Additional 19F signal is observed in the vasculature as well as the liver and
spleen, which are included in the mechanism by which the PFCE particles are cleared.

Figure 5.1 (a) 1H TSE image of unilateral permanent occlusion of renal artery in rat left kidney.
(b) 19F bFFE image of PFCE NP emulsion injected i.v. (3 ml/kg). Location of kidneys outlined
in red (arrow: injured left kidney). (c) 19F image false-colored in green overlaid on 1H image.
Figure 5.2 demonstrates the capability of

19

F MRI to distinguish cortical (C) from

medullary (M) renal perfusion, labeled in (Fig. 5.2a), in vivo at 3T (b-g). Compared to a normal
control rat (b&c), the permanently occluded left kidney (d) shows no discernable signal, and the
45-min injured kidney shows lower medullary signal (f) than its contralateral control (g). The in
vivo AKI imaging is supported by ex vivo imaging that qualitatively shows lower medullary
signal in the injured kidney (h) as compared to its contralateral control (i).
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Figure 5.2 (a) 1H TSE image of ex vivo rat kidney cross-section showing cortex [C] and medulla
[M]. In vivo rat kidney cross sections showing renal perfusion via 19F imaging of PFCE NP
emulsion (3 ml/kg) in the following: (b, c) normal controls-L, R; (d, e) permanently occluded-L,
contralateral control-R; (f, g) ischemia/reperfusion-L, contralateral control-R. (h, i) Ex vivo 19F
imaging of ischemia/reperfusion-L, contralateral control-R.
After feasibility of renal imaging with 19F MRI of PFC NPs at 3T was established with
proof of concept in vivo and ex vivo results, the ability to quantitate renal perfusion was tested in
an additional in vivo experiment. Figure 5.3 displays the results of this in vivo warm
ischemia/reperfusion rat model of AKI. A 1H cross-sectional image of the rat (Fig. 5.3a) shows
the left, injured kidney (with cortex, corticomedullary junction, and medulla delineable) and the
external 19F standard outlined in red. 19F MR imaging with a 19F/1H bFFE sequence can be used
to quantify circulating PFCE NPs (3 ml/kg for 5 min) (Fig. 5.3b); by comparison to the external
19

F PFCE standard (150 mM19F), lower renal perfusion is observed in the medulla (63.8 ± 10.9

mM19F) than in the cortex (82.8 ± 6.9 mM19F) of the injured left kidney.
Colocalization of the
overlaying the

19

19

F signal in the kidney and external standard are confirmed by

F signal (green) on the 1H signal in Figure 5.3c, which shows additional

19

F

signal in the vasculature, spine, and likely a portion of the spleen. A B1 map of the same imaging
slice (Fig. 5.3d) demonstrates the homogeneity of the RF field produced by the 19F/1H dual-tuned
solenoid coil, with the percent actual/requested flip angle achieved in the 19F standard (95.2 ± 6.0
%) nearly the same as in the kidney (95.9 ± 3.4 %), as measured by actual flip angle imaging
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(AFI). As such, B1-mapping compensation (as presented in Chapter 4) was not needed here since
it yielded the same quantitative results as the non-compensated image.

Figure 5.3 (a) Cross-sectional 1H image of rat anatomy, showing left injured kidney in an
ischemia/reperfusion model of AKI and external 19F standard outlined in red. (b) 19F MR image
using simultaneous 19F/1H bFFE sequence of PFCE NP emulsion (3 ml/kg) circulating for 5 min.
Compared to external PFCE standard (150 mM19F), 19F signal was quantified in the kidney,
which showed lower renal perfusion in the medulla (63.8 ± 10.9 mM19F) than in the cortex (82.8
± 6.9 mM19F). (c) 19F image overlaid in green on 1H image showing colocalization of standard
and renal 19F signal. (d) B1 map using AFI (% actual/requested flip angle) demonstrating that
nearly the same flip angle was achieved in the 19F standard (95.2 ± 6.0 %) as in the kidney (95.9
± 3.4 %) with the 19F/1H dual-tuned solenoid coil.
Although homogeneous in the plane transverse to the long axis of the coil, the RF field
produced along the solenoid coil’s long axis (Figure 5.4) exhibits a characteristically
inhomogeneous B1 field outside the well-defined field of view. This highlights the need for
appropriate placement of the animal inside the solenoid coil, which is confirmed with a series of
scout scans at the beginning of an imaging experiment.

Figure 5.4 (a) Long-axis 1H image of rat anatomy, showing left injured kidney in an
ischemia/reperfusion model of AKI outlined in red. (b) B1 map using AFI (% actual/requested
flip angle) showing homogeneous RF field within field-of-view (FOV) (~ 5 cm long) of 19F/1H
dual-tuned solenoid coil (c), which falls off outside coil FOV.
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5.1.4 Discussion
These data confirm that renal perfusion can be imaged at clinical field strengths with
simultaneous

19

F/1H MRI of circulating PFC NPs.

19

F MRI of injured kidneys qualitatively

reveals reduced signal from PFC NPs in the medulla as compared with contralateral controls,
denoting decreased local renal perfusion. Furthermore, qualitative in vivo and ex vivo imaging
results are confirmed by quantitative 19F MRI, which show reduced medullary renal perfusion by
comparison to an external 19F standard.
Interestingly, the B1 field produced by this solenoid coil, when properly placed in the coil
FOV, is quite homogeneous and did not necessitate B1-mapping compensation. Instead of
invalidating the B1-mapping compensation technique of Chapter 4 (especially since the flip angle
calibration technique was still necessary here), this suggests that small, homogeneous

19

F/1H

dual-tuned solenoid coils can be used for small animal experiments, as in this rat experiment,
without the need for post-processing. However, when the imaging geometry requires a nonsolenoidal coil, as in human kidney imaging applications, this technique will be valuable to
ensure quantitative 19F renal imaging results match those found in preclinical settings.

5.1.5 Conclusion
This study presented and validated a technique to use quantitative

19

F MRI to detect

accumulation of circulating PFC NPs as a means to measure local renal perfusion, which was
importantly shown at 3T. The ability to noninvasively image and quantify renal perfusion at
clinical field strengths affords many other potentially translatable applications of kidney imaging
with 19F MRI in the clinic. Recent work by this group has demonstrated that direct targeting and
pharmaceutical knockdown of activated thrombin at the sites of acute kidney injury with a
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selective

PFC

NP-based

thrombin

inhibitor,

PPACK

(phenylalanine-proline-arginine-

chloromethylketone), improves kidney reperfusion and protects renal function after transient
warm ischemia (Chen, Vemuri, Goette, et al. In review). Additionally, 19F MR has been shown to
exploit variations in blood pool T1 relaxation to quantify renal oxygenation, because
inversely proportional to the local oxygen content (pO2) (7,10). Thus,

19

19

F T1 is

F MR with PFC NP

emulsions offers a promising opportunity to image and quantify renal perfusion in AKI on
clinical MR scanners.

5.2 Quantifying the Impact of Diet-Induced Atherosclerotic Plaque Erosions with 19F MRI
5.2.1 Introduction
Atherosclerosis is the leading cause of death in the developed world, manifesting high
morbidity and mortality as a consequence of recurrent acute vascular events that are nearly
unpredictable in individuals despite maximal medical therapy (11,12). Recent focus on the
pathophysiology of atherosclerosis has shifted to the wide array of inflammatory cell types and
necrotic debris that engage a host of prothrombotic signaling events resulting in acute focal
clotting and vascular obstruction, unstable angina, and infarction (13,14). Pathological studies on
victims of acute coronary syndromes (15,16) have suggested that these acute vascular events are
a consequence of plaque erosions in 33% of cases, which are not necessarily associated with
plaque ruptures (17,18).
Disruption of the normally anti-thrombotic endothelial layer in an atherosclerotic vessel
results in exposure of circulating blood elements to a reservoir of inflammatory cell types, lipids,
cytokines, and coagulation factors that contribute to a pro-inflammatory hypercoagulable state
(19). Early descriptions of the “vulnerable plaque” by Ambrose and others were expressed in
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terms of a propensity to focal thrombosis rather than morphological or biochemical descriptors
(20,21). Yet regardless of the definition, there are still no predictive data that delineate
endothelial barrier disruption in patients with atherosclerosis and their related propensity to focal
thrombosis, because no generally applicable noninvasive techniques are available for their
detection prior to death and autopsy.
We recently reported the development of a long-term dietary regimen and an MR
molecular imaging approach for the detection and quantification of plaques accumulating
semipermeant PFC nanoparticles at 11.7 T, as a potential diagnostic surrogate for endothelial
barrier disruption (22).

19

F MRI allowed specific localization and quantification of the

concentration of PFC NPs in endothelial barrier disrupted plaques in older rabbits ex vivo, as
well as in human carotid endarterectomy samples that were incubated ex vivo with the PFC NPs.
Our goal here is to quantify the presence of diet-induced erosions by passive accumulation of
nontargeted PFC NP emulsion in an in vivo atherosclerotic animal model at clinical field
strength. Accordingly, we show that atherosclerotic plaque erosions are detectable by 19F MRI at
3T, suggesting a clinically translatable strategy for quantitative plaque staging in terms of
endothelial barrier disruption.

5.2.2 Methods
5.2.2.1 Atherosclerotic Animal Model
All procedures were performed with approval from the Washington University Animal
Studies Committee. Male New Zealand White rabbits were maintained on a Western diet,
consisting of 0.25% cholesterol feed (Cat. 9433, TestDiet, St. Louis, MO) for 9 months. This
hyperlipidemic rabbit model has been consistently shown to generate significant atherosclerotic
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plaque burden throughout arterial vessels (23). For control images without plaque development,
young rabbits were fed normal chow. Both control and atherosclerotic rabbits were anesthetized
and given a 1 ml/kg intravenous bolus of nontargeted PFC nanoparticles 2-3 hours prior to

19

F

MRI.

5.2.2.2 In Vivo 19F MR Molecular Imaging
The imaging study was performed on a 3T clinical whole-body scanner (Achieva, Philips
Healthcare, The Netherlands), outfitted with a dual
resonant

19

19

F/1H spectrometer system (24). A dual-

F/1H surface RF coil was used (15×15 cm), which can either transmit or receive at

both resonance frequencies simultaneously (25). Imaging was performed 3h post-injection of 1.0
ml/kg PFC NP with perfluoro-15-crown-5-ether (PFCE; C10F20O5) core as previously described
(26). To avoid signal contamination from inhaled fluorinated anesthesia, a xylazine (10mg/kg) /
ketamine (85 mg/kg) i.m. injection was used for anesthesia induction, which was maintained
with a ketamine i.v. infusion (18 mg/kg/hr). A 2D simultaneous 19F/1H bFFE sequence was used
with the following parameters: FOV = 128×128 mm, matrix = 96×96, slice thickness = 20 mm,
voxel size = 1.33×1.33×20 mm, α = 25°, exBW = 5 kHz centered on single PFCE peak, pBW =
500 Hz, TR/TE = 14/1.72 ms, 1000 NSA, and a scanning time of 33 minutes.
Employing the above technique without alteration, however, would yield 19F signal from
both the PFC NP located in the plaque as well as the circulating blood pool. Although some
protocols have been used to selectively eliminate certain 19F NMR peaks, such as chemical shift
selective (CHESS) saturation (27), or to generate contrast by saturation recovery as in blood
flow-enhanced-saturation-recovery (BESR) (28), no protocols were found to selectively
eliminate

19

F signal in flowing blood. Selective saturation of spins with the regional saturation
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technique (REST) is typically used to eliminate 1H signal from fat surrounding a particular
region of interest, and was investigated here as a method to eliminate 19F signal from the blood
pool, leaving only 19F signal from PFC NPs in plaque erosions. Two parallel saturation bands 30mm in thickness both 10-mm proximal and distal to the imaging slice were applied to eliminate
19

F signal from the blood pool, using REST slabs at the PFCE resonance frequency, after testing

to confirm REST slab effectiveness on 19F nuclei.
The imaging slice was centered on the abdominal aorta, located 2-3 cm distal to the renal
artery via an angiogram consisting of a multi-2D time-of-flight gradient echo sequence with the
following parameters: FOV = 100×78 mm, matrix = 112×112, slice thickness = 2 mm, α = 60°,
TR/TE = 13.54/4.06 ms, 4 NSA, and a scanning time of 3 minutes. After anatomical
colocalization of

19

F signal was confirmed with the simultaneously acquired 1H image, a high-

resolution gradient echo 1H image was used to display the overlaid 19F signal with the following
parameters: FOV = 128×128 mm, matrix = 256×256, slice thickness = 4 mm, voxel size =
0.5×0.5×4 mm, α = 35°, TR/TE = 25.16/7.02 ms, 23 NSA, and a scanning time of 2.5 minutes.

5.2.2.3 Histology
Histological sections were created from samples of the fat-fed and control rabbit aortas,
and analyzed for lipid content by light microscopy with an oil red O stain (29). Sections of rabbit
aorta from hyperlipidemic and normal rabbits were frozen in O.C.T. media and cryosectioned
into 8 µm slices, dried, and fixed in 10% formalin. After rinsing with 60% isopropanol, sections
were stained with a freshly prepared 0.3% oil red O (Sigma-Aldrich, St. Louis, MO) working
solution in isopropanol for 15 min, followed by another 60% isopropanol rinse (30). Nuclei were
lightly stained with alum haematoxylin and rinsed with distilled water, and finally the sections
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were mounted on slides with aqueous mountant. Microscopy was performed under 100X
magnification.

5.2.3 Results
Figure 5.5 shows the proof-of-concept experiment to refine the in vivo 19F MRI protocol
in a control rabbit. Within three minutes of the 1 ml/kg nontargeted PFC NP emulsion injection
(instead of the typical 2-3 hour circulation time), 19F MR imaging was performed to test the coil
performance and effectiveness of REST slab saturation. Figure 5.5a shows a long-axis view of
the rabbit, with 19F signal detectable in the aorta, liver, and kidney, confirmed with colocalization
in the

19

F/1H overlay image (Fig. 5.5c). A REST slab perpendicular to the imaging slice (Fig.

5.5e) was used to saturate the 19F spins from the aorta and liver, which was successful, as seen in
Figure 5.5b&d. However, since the saturation band was applied in the imaging slice, all

19

F

signal was eliminated from that portion of the image. Figure 5.6 displays resultant crosssectional

19

F images using one parallel saturation band proximal to the imaging slice in the

control rabbit, which successfully eliminates only aortic 19F signal from circulating PFC NPs.
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Figure 5.5 19F MRI of 1 ml/kg PFC NP emulsion injected into normal chow rabbit 3 min prior to
imaging. (a) 19F bFFE image without REST slab shows long-axis view of the rabbit, with 19F
signal detectable in aorta, liver, and kidney, confirmed with colocalization in 19F/1H overlay
image (c). A REST slab perpendicular to the imaging slice eliminates 19F signal from image (b &
d). REST slab and imaging slice location (e).

Figure 5.6 Cross-sectional 19F MR images without (a) and with (b) one parallel REST slab
proximal to the imaging slice, which eliminates only aortic 19F signal from circulating PFC NPs,
confirmed with 19F overlays (green) on 1H images (c & d).
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Upon further investigation with other experimental iterations, it was determined that two
30-mm thick REST slabs 10-mm proximal and distal to a cross-sectional imaging slice would
provide optimum saturation of 19F signal from flowing aortic and venous blood, while allowing
for sensitive 19F MR detection of PFC NPs in plaque. The position of these REST slabs can be
seen in Figure 5.7, which also shows an overlay of the angiogram that was used for slice
positioning in the control and atherosclerotic rabbits.

Figure 5.7 Locations of saturation bands used to eliminate 19F signal from flowing blood
proximal and distal to imaging slice (which continued beyond the image FOV). Aorta, shown in
red, was imaged with a time-of-flight angiogram. [Figure reprinted from Palekar, Goette, et al. In
preparation]
To demonstrate the potential for in vivo delineation of endothelial barrier disruption with
a clinical 3T MRI scanner,

19

F MRI was performed on rabbits with or without diet-induced

atherosclerotic plaque and erosions (Fig. 5.8). Proton images of abdominal cross-sections (Fig.
5.8a&d) show the position of the aorta in rabbits fed normal chow and Western diet,
respectively. Figure 5.8e shows the 19F MR signature after PFC NP circulation for 180 minutes
in the hyperlipidemic rabbit. Compared to an external standard of PFCE NP in agar (150
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mM19F), the aortic plaque

19

F signal was quantified as 26.1 mM19F. Note the suppression of

luminal blood 19F signal in normal chow rabbit (Fig. 5.8b) due to saturation band placement (Fig.
5.7), indicating that no signal arises from the circulating PFC NP in the blood pool. Figure
5.8c&f displays

19

F/1H overlays showing the aortic and adjacent vena cava wall

19

F signal

(green) emanating from PFC NP permeating into arterial plaques, and interestingly into inflamed
venous structures under the same hyperlipidemic drive (31,32). Figure 5.8c demonstrates that in
a healthy rabbit, no measurable nanoparticle retention occurs in the aorta or vena cava. Figure
5.8g&h shows representative oil red O stains of the previously imaged regions of interest
showing aortic lipid-containing plaque elements in the normal chow rabbit and cholesterol fed
rabbit, respectively.

Figure 5.8 Cross-sectional 1H images of (a) normal chow rabbit and (d) cholesterol fed rabbit
showing location of abdominal aorta (red box). 19F bFFE images of PFCE nanoparticle 19F signal
in the region of interest for (b) normal chow rabbit and (e) cholesterol fed rabbit. Saturation
bands proximal and distal to imaging slice eliminate 19F signal from blood. 19F signal (green)
overlaid on 1H image showing 19F signal colocalization for the region of interest in a (c) normal
chow rabbit and (f) cholesterol fed rabbit, demonstrating deposition of PFC-NP only in inflamed
abdominal aorta (AA) and vena cava (VC). Representative oil red O stains of the imaged area
showing plaque elements in (g) normal chow rabbit and (h) cholesterol fed rabbit. Scale bars
denote 500 µm. [Figure reprinted from Palekar, Goette, et al. In preparation]
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5.2.4 Discussion
These data show that atherosclerotic plaque erosions infiltrated by passive accumulation
of nontargeted PFC NP emulsion are detectable by

19

F MRI of at 3T. Two REST slabs, at a

frequency matching that of the PFCE NPs, parallel to the cross-sectional imaging slice
successfully eliminated

19

F signal from the blood pool, allowing for the direct imaging and

quantification of accumulated emulsion. Quantification was performed by comparison of the
isolated 19F signal from the aortic plaque to an external standard of known concentration at the
same distance away from the 19F/1H dual-tuned coil. Although the RF field was not mapped for
this study, a B1-mapping compensation as presented in Chapter 4 would ensure accuracy and
repeatability of these measurements over time and across sites.
Note that the voxel size required for recording a sufficient

19

F signal to enable fluorine

MRI necessarily yields a comparatively low-resolution 19F image in the rabbit (Fig. 5.8b&e), as
contrasted with the 1H image. However, the ability to image voxels containing PFC NP at 3T on
a multispectral clinical scanner in rabbits suggests that this approach might be sufficient for
human MRI where higher voxel fluorine concentrations might be achieved to enhance sensitivity
due to the greater masses of tissues involved. The present results also suggest potential for
adding value in the detection of individuals prone to thrombosis based on delineation of the
"anatomical burden of atherosclerosis," as recently discussed by Mancini et al (33) as a predictor
of vascular outcomes, with the use of non-invasive MRI quantification of biocompatible
nanoparticles bearing a direct relationship to hypercoagulability.
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5.2.5 Conclusion
This study demonstrated the potential to image atherosclerotic plaque erosions with
accumulation of nontargeted PFC NP at clinical field strengths. Although further in vivo
evaluation will be required to assess translational relevance of this approach, the in vivo 3T 19F
MRI data obtained in this and other settings suggests feasibility (26,34).
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Chapter 6. Imaging of Peripheral Arterial Disease in Amputated
Human Lower Extremity Specimens

As a step beyond preclinical imaging, but before a full clinical trial, human tissue
specimens offer an opportunity to image in real-world applications, but without the need for
extensive clinical trials. One such study was designed and approved, which involved the
procurement of amputated human lower extremity specimens with peripheral arterial disease
from the department of surgery. The work is presented here as a pilot project for human
atherosclerosis imaging with nontargeted PFC NP at 3T, instead of in Chapter 5, because only
one specimen was procured and imaged. The initial phantom and human specimen results,
however, are promising and are a strong candidate for furthering the work of this thesis.

6.1 Introduction
Peripheral arterial disease (PAD) has a total disease prevalence of up to 10% in the
general population and in up to 20% of the US population over the age of 70 (1). Symptoms may
range from mild cramping while walking to debilitating pain at rest. Current medical and
surgical therapies for patients with PAD are aimed at temporizing the disease process and
providing symptom relief. Unfortunately, many patients become debilitated with intractable pain
or have to undergo lower extremity amputation (2). Nanotechnology may be able to fill the
significant clinical need to diagnose atherosclerotic disease earlier and to halt or reverse disease
progression by imaging and potentially treating the disease with nanoparticles (3). Our
laboratory has made significant progress in the creation and testing of PFC nanoparticles specific
to cardiovascular disease, with extensive work with in vitro and in vivo animal models, as well as
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human vascular tissue specimens (4-9). While we have characterized the behavior in sections of
tissue or plaques (10), the behavior, ability to image and therapeutic potential in intact human
vasculature is not known. This study entails the perfusion of nanoparticles into intact vasculature
in lower extremity amputation specimens. The specific particles used will include those we have
studied in the past for cardiovascular imaging and for local thrombin inhibition (5). We
hypothesize that these particles will localize to areas of atherosclerotic disease, will be able to be
detected by 19F MRI, and therefore, may be useful in the diagnosis and targeted therapy of PAD.

6.2 Methods
A phantom was first designed and constructed to mimic blood flow and imaging
properties of a human lower leg specimen by encasing tubing (~ 3 mm diameter) within 2% agar
inside of a 2 L bottle (Fig. 6.2b). The tubing was connected to an anesthesia infusion pump,
rigged as a continuous circuit, with a flow rate of 600 ml/hr (10 ml/min) resulting in a flow
velocity of approximately 8 cm/s in the tubing. 1H MR angiography (MRA) was performed by
circulating 1% saline doped 5000:1 with Gd3+, and 19F MRI was performed with static PFCE NP
emulsion in the tubing. This human specimen portion of the study was performed in accordance
with protocols approved by the Departments of Surgery and Pathology at Washington University
in St. Louis. Amputated human lower extremity specimens were obtained directly from the
surgical operating room from patients who had undergone amputation for terminal peripheral
vascular disease. The intact arterial vasculature of these limbs was cannulated and immediately
perfused with a solution containing 1% saline, 4% sodium citrate, and 0.01% heparin, using the
previously-mentioned portable pump system at 600 ml/hr.
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MR data were acquired on a 3T clinical whole-body scanner (Achieva, Philips
Healthcare, Best, The Netherlands) with a dual

19

F/1H spectrometer system and a dual-tuned

transmit/receive semi-cylindrical RF coil (7×12 cm) (Fig. 6.2a). MRA was first performed on the
flowing saline solution, using a multiple-2D time-of-flight (M2D TOF) sequence with a REST
slab to eliminate return flow distal to the imaging slice, using the following parameters: 120 mm
FOV, matrix 1123, 69 2-mm slices, α = 60°, TR/TE = 12.83/3.94 ms, NSA = 11, 3.3 min scan
time. Maximum-intensity-projections (MIP) were reconstructed by the scanner software from the
stack of MRA images in all three orthogonal imaging planes. A similar sequence was tested on
the phantom with and without REST slabs.
PFC NP emulsion with a perfluoro-15-crown-5-ether core and a PPACK antithrombotic
agent was circulated at 2 ml/kg for 2 hours during

19

F imaging. A simultaneous

19

F/1H 3D

balanced UTE-SSFP imaging sequence with Wong-type (11) 3D radial readout trajectory (as
presented in Chapter 3) was used with 140 mm FOV, matrix 643, isotropic voxel Δx = 2.3 mm,
exBW = 4 kHz centered on PFCE peak, pBW = 400 Hz, α = 30°, TR/TE = 2.32/0.13 ms, Nyquist
radius = 0.23, NSA = 56, 35 min scan time. For the phantom experiment, a simultaneous 19F/1H
2D bFFE sequence was also used with 140 mm FOV, matrix 128×128, 3 mm slice thickness,
exBW = 4 kHz centered on the single PFCE peak, pBW = 500 Hz, α = 25°, TR/TE = 4.198/2.10
ms, NSA = 500, 5 min scan time. The B1 field was mapped using an actual flip-angle imaging
(AFI) sequence with: 140 mm FOV, 962 matrix, 15 4-mm slices, 1.4×1.4×0.6 mm resolution, α =
70°, 2.8 min scan time.
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6.3 Initial Results
Figure 6.1a shows T1-weighted 1H FFE coronal images of leg phantom. MR angiography
(MRA) of phantom was performed with flowing (~ 8 cm/s) saline doped 5000:1 with Gd3+ using
M2D TOF (multiple 2D, time-of-flight) 1H imaging with REST slab position (Fig. 6.1b). A
MRA maximum intensity projection (MIP) and MIP overlay onto the 1H image without (Fig.
6.1c&d) and with a REST slab (Fig. 6.1e&f) demonstrate the ability to saturate the spins in the
return flow.

Figure 6.1 (a) T1-weighted 1H FFE coronal image of leg phantom. Setup of MR angiography of
phantom with flowing (~ 8 cm/s) saline doped 5000:1 with Gd3+ using M2D TOF (multiple 2D,
time-of-flight) 1H imaging with REST slab position (b). MRA maximum intensity projection
(MIP) and MIP overlay on 1H image without (c&d) and with a REST slab (e&f) saturating the
spins in the return flow.
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Figure 6.2a displays the semi-cylindrical

19

F/1H dual-tuned coil, as well as the leg

phantom, consisting of tubing encased within 2% agar in 2 L bottle (Fig. 6.2b). Actual flip angle
imaging (% actual/requested flip angle) maps in the transverse (Fig. 6.2c) and sagittal (Fig. 6.2e)
views with corresponding profile plots (Fig. 6.2d&f) demonstrate signal drop-off with increasing
in distance away from the coil (illustrated in red).

Figure 6.2 (a) Semi-cylindrical 19F/1H dual-tuned coil. (b) Leg phantom, consisting of tubing
encased within 2% agar in 2 L bottle. Actual flip angle imaging (% actual/requested flip angle)
maps in the transverse (c) and sagittal (e) views with corresponding profile plots (d & f)
increasing in distance away from the coil (location illustrated in red).
Figure 6.3 exhibits T1-weighted 1H FFE transverse (Fig. 6.3a) and coronal (Fig. 6.3b)
images of the leg phantom. Simultaneous 19F/1H imaging of PFCE NP emulsion in leg phantom
tubing is performed using a bFFE sequence in transverse (Fig. 6.3c) and coronal (Fig. 6.3d)
planes. Note the banding artifacts from the coil and imaging protocol that are present in the
coronal slice. Figure 6.3e show a

19

F image using balanced UTE-SSFP sequence in the

transverse plane, along with a coronal MIP (Fig. 6.3f).
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Figure 6.3 T1-weighted 1H FFE transverse (a) and coronal (b) images of leg phantom.
Simultaneous 19F/1H imaging of PFCE NP emulsion in leg phantom tubing (static) using bFFE
sequence in transverse (c) and coronal (d) planes. Note: banding artifacts from coil are present in
coronal slice. 19F image using balanced UTE-SSFP sequence in transverse plane (e), with
coronal MIP (f).
Imaging of the human lower leg specimen is displayed in Figure 6.4, demonstrating MR
angiography of the leg with flowing (600 ml/hr) saline using M2D TOF (multiple 2D, time-offlight) 1H imaging. Maximum intensity projections (MIP) in coronal (Fig. 6.4a), sagittal (Fig.
6.4b), and transverse (Fig. 6.4c) planes are displayed. The MRA setup and slice orientation can
be seen in Figure 6.4d.
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Figure 6.4 MR angiography of leg with flowing (600 ml/hr) saline using M2D TOF (multiple
2D, time-of-flight) 1H imaging. Maximum intensity projections (MIP) in coronal (a), sagittal (b),
and transverse (c) planes. MRA setup and slice orientation (d).
Figure 6.5a shows a high-resolution T1-weighted 1H FFE transverse image of the leg
anatomy (arrow: cannulated artery). Figure 6.5b demonstrates 19F imaging of PFCE NP emulsion
(~ 2 ml/kg) in the cannulated artery using a balanced UTE-SSFP sequence in the transverse
plane.

Figure 6.5 (a) High-resolution T1-weighted 1H FFE transverse image of leg anatomy (arrow:
cannulated artery). (b) 19F imaging of PFCE NP emulsion (~ 2 ml/kg) in artery using balanced
UTE-SSFP sequence in transverse plane. Other 19F signal from PFC NP emulsion that pooled
outside the specimen due to leaking from an absence of a return circuit.
6.4 Discussion
This proof-of-concept pilot study shows how a molecular imaging experiment goes from
conception to phantom imaging to ultimate application in human tissue. Although more work is
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required to optimize the protocol (i.e. a return circuit to circulate PFC NPs) and more specimens
will be required to reach significance, this study offers a promising direction for future research.

6.5 Acknowledgements
I would like to thank Dr. Chandu Vemuri, a vascular surgeon in the Department of
Medicine, who was vital to the approval of this protocol. My role in the work was to design the
phantom experiment and perfusion setup, assist Dr. Vemuri in the operating room on the day of
procurement, and perform all imaging and analysis.

6.6 References
1.

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Group TIW.
Inter-society consensus for the management of peripheral arterial disease (TASC II). J
Vasc Surg 2007;45 Suppl S:S5-67.

2.

Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J,
Gornik HL, Halperin JL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White
JV, Zierler RE. 2011 ACCF/AHA focused update of the guideline for the management of
patients with peripheral artery disease (updating the 2005 guideline): a report of the
American College of Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines. J Am Coll Cardiol 2011;58(19):2020-2045.

3.

Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G. Applications of
nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscl Throm
Vas 2006;26(3):435-441.

139

4.

Pan H, Myerson JW, Hu L, Marsh JN, Hou K, Scott MJ, Allen JS, Hu G, San Roman S,
Lanza GM, Schreiber RD, Schlesinger PH, Wickline SA. Programmable nanoparticle
functionalization for in vivo targeting. FASEB J 2013;27(1):255-264.

5.

Myerson J, He L, Lanza G, Tollefsen D, Wickline SA. Thrombin-inhibiting
perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic
resonance imaging of acute thrombosis. J Thromb Haemost 2011;9(7):1292-1300.

6.

Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, Robertson JD,
Gaffney

PJ,

Lanza

GM,

Wickline

SA.

Quantitative

"magnetic

resonance

immunohistochemistry" with ligand-targeted 19F nanoparticles. Magn Reson Med
2004;52(6):1255-1262.
7.

Kaneda MM, Caruthers S, Lanza GM, Wickline SA. Perfluorocarbon nanoemulsions for
quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng
2009;37(10):1922-1933.

8.

Hu G, Lijowski M, Zhang H, Partlow KC, Caruthers SD, Kiefer G, Gulyas G, Athey P,
Scott MJ, Wickline SA, Lanza GM. Imaging of Vx-2 rabbit tumors with αvβ3- integrintargeted 111In nanoparticles. Int J Cancer 2007;120(9):1951-1957.

9.

Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen
JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of
angiogenesis in early-stage atherosclerosis with αvβ3-integrin-targeted nanoparticles.
Circulation 2003;108(18):2270-2274.

10.

Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA,
Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging

140

of fibrin implications for detecting vulnerable plaques. Circulation 2001;104(11):12801285.
11.

Wong STS, Roos MS. A strategy for sampling on a sphere applied to 3D selective RF
pulse design. Magn Reson Med 1994;32(6):778-784.

141

Chapter 7. Conclusion

The objective of this thesis was to advance the state of the art for

19

F MR molecular

imaging of perfluorocarbon nanoparticle emulsion contrast agents. It is the assertion of this
dissertation that this objective was achieved in the following ways: (1) new tools and techniques
for 19F MR molecular imaging of PFC nanoparticles were created, (2) translatable procedures for
absolute quantification of

19

F nuclei with MR molecular imaging were developed, (3) the

potential for clinical translation with ex vivo and in vivo preclinical experiments was evaluated.

7.1 Summary of Major Findings
In Chapter 2, the underlying principles behind 19F NMR physics and image acquisition
were explored, as well as the unique properties of 19F/1H dual-tuned RF coils. The NMR physics
governing all magnetically susceptible nuclear spins was reviewed, and distinctions were drawn
between 1H atoms and

19

F nuclei. Then, resultant magnetic resonance properties of

19

F spins,

such as J-coupling, were examined, along with their effect on perfluorocarbon molecules like
PFOB. The theory behind image acquisition with

19

F/1H dual-tuned RF coils was then

considered, which included a coupled resonator model with appropriate impedance matching. A
new dual-tuned single-turn-solenoid RF coil was designed and constructed to open up new
applications for simultaneous 19F/1H imaging. Experimental results with this new coil were then
presented, including bench tests of electromagnetic performance, as well as phantom and in vivo
imaging experiments.
Chapter 3 introduced a new pulse sequence, termed “balanced UTE-SSFP”, for highly
sensitive

19

F MR imaging of agents with complex spectra. The NMR properties of molecules
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with non-proton nuclei such as PFOB were discussed to understand their broad chemical shifts
and complex relaxation characteristics. Then, the CF2 spectral peak signatures of PFOB were
modeled, which quickly dephases and decays due to T2 relaxation, but can be utilized if acquired
quickly. A new 3D 19F/1H pulse sequence was then designed and implemented to capture these
CF2 resonances, which consists of

19

F/1H RF excitation using FID acquisition at an ultra-short

echo time (UTE) and a balanced steady-state free precession (SSFP) gradient scheme with a
Wong-type 3D radial readout trajectory. The sensitivity of this new balanced UTE-SSFP pulse
sequence was compared to existing sequences, and shown to have a sensitivity twofold better
than other sequences. Finally, in vivo imaging of angiogenesis-targeted PFOB nanoparticles was
demonstrated in a rabbit model of cancer on a clinical 3T scanner, to validate the translational
potential for the new pulse sequence.
In Chapter 4, a new approach to overcome challenges for accurate in vivo quantitative 19F
MR molecular imaging was presented, which includes flip angle calibration between the relevant
1

H and

19

F nuclei of interest, as well as B1-mapping compensation to offset expected RF

inhomogeneities. A disparity in the required power settings of
achieve optimum flip angles for the

19

19

F/1H dual-tuned RF coils to

F and 1H nuclei was reported and investigated. Then, an

approach to remediate this difference in requisite power settings was proposed and tested, which
involves a coil-specific, but spatially independent calibration ratio for each coil. This strategy
permitted determination of the optimum power setting for the 19F nuclei by utilizing the abundant
1

H signal as a reference. A solution to inhomogeneous RF fields was proposed that entailed

mapping the B1 field and performing an image-based correction using a signal model of the
acquisition technique, which was tested in phantom and in vivo experiments in a rabbit model of
cancer.
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Chapter 5 examined two in vivo applications of 19F MR molecular imaging at 3T. First, a
new technique to image renal perfusion in acute kidney injury (AKI) at clinically relevant field
strengths was presented. A model of AKI was implemented in rats by ligation and occlusion of
the left renal artery, followed by reperfusion. Renal perfusion was then imaged at 3T with a
19

F/1H dual-tuned coil after administration of PFC NPs via the tail vein. These in vivo results

were confirmed with ex vivo imaging of excised kidneys. Next, the impact of diet-induced
atherosclerotic plaque erosions was investigated with quantitative

19

F MRI of a hyperlipidemic

rabbit model in vivo. A method was introduced and tested to visualize nontargeted PFC
nanoparticles that accumulate passively in the intimal plaque regions of the rabbit aorta as a
consequence of endothelial erosions and vascular barrier disruption with the use of

19

F MR

molecular imaging combined with saturation bands to eliminate signal from the flowing blood
pool, which allowed 19F imaging of the vessel wall itself.
Chapter 6 investigated the potential use of 19F MR molecular imaging at 3T in the clinic
with a pilot study of atherosclerosis imaging using nontargeted PFC NP in human tissue
specimens. Initial imaging results in a phantom and an amputated human lower limb were
presented, which show promise for the use of 19F imaging in human atherosclerosis imaging in
the future.

7.2 Future Work
7.2.1 19F/1H Dual-Tuned RF Coils
As new applications of 19F MR molecular imaging of PFC NP emulsions arise, there are
new opportunities to design and build specialized 19F/1H dual-tuned coils. One such opportunity
arose during the renal imaging study (section 5.1), when a coil specific to the rat kidney anatomy
144

could have provided more

19

F sensitivity and better image quality. This coil was designed and

simulated in SPICE (Figure 7.1), and consisted of a unique transmit/receive switch that would
allow for simultaneous

19

F/1H imaging with whole-(rat)-body transmission using an outer coil

element and focused receiving using an inner coil element. However, this design was not built,
so this could be a future direction stemming from this work.

Figure 7.1 Unique 19F/1H dual-tuned coil design (left) and circuit diagram (right) with active
switching, allowing for transmission using an outer coil element and reception using an inner
coil element.
In addition to this design with different physics transmit/receive elements, the ability to
perform the flip angle calibration and B1-mapping compensation presented in Chapter 4 could be
evaluated with this type of coil, as well as other single-tuned coils. It was hypothesized that the
flip angle calibration would require dual-tuned coils with the same physical element, and that the
B1-mapping compensation could potentially work with single-tuned coils with the same physical
coil elements. This hypothesis would be an interesting direction for future work.

7.2.2 Human In Vivo Applications
The ultimate goal of this work, in addition to the aspiration of most all molecular imaging
scientists, is to translate the imaging techniques tested in phantom and preclinical experiments
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into the clinic. The potential applications of this work are numerous, and include cancer and
atherosclerosis imaging with ανβ3-integrin targeted or nontargeted PFC NP emulsions (1). In
addition, the renal imaging work offers a promising opportunity to image human kidneys in
patients who have acute kidney disease, especially since no potentially harmful Gd-containing
agents are necessary. Of course, however, all human applications require years of development
and thorough testing of agents and protocols before they can be implemented in clinical trials.
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